

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Platelet-rich fibrin/anorganic bovine bone mineral complex as grafting materials in endodontic microsurgery with a large lesion size: study protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057068
Article Type:	Protocol
Date Submitted by the Author:	03-Sep-2021
Complete List of Authors:	Han, Bing; Peking University School of Stomatology, Department of Cariology and Endodontology Wang, Yuhua; Peking University School of Stomatology, Department of Cariology and Endodontology Chen, Zhibin; Peking University School of Stomatology, Department of Periodontology Zheng, Chunyan; Peking University School of Stomatology, Department of Cariology and Endodontology Zhang, Zhichun; Peking University School of Stomatology, Department of Cariology and Endodontology Liu, Yingyi; Peking University School of Stomatology, Department of Cariology and Endodontology Liu, Kaining; Peking University School of Stomatology, Department of Periodontology Wang, Zuhua; Peking University School of Stomatology, Department of Cariology and Endodontology Wang, Xiaoyan; Peking University School of Stomatology, Department of Cariology and Endodontology
Keywords:	Clinical trials < THERAPEUTICS, ORAL MEDICINE, ORAL & MAXILLOFACIAL SURGERY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Platelet-rich fibrin/anorganic bovine bone mineral complex as grafting materials**  
5 **in endodontic microsurgery with a large lesion size: study protocol for a**  
6 **randomised controlled trial**  
7  
8  
9

10  
11 Bing Han<sup>1</sup>, Yuhan Wang<sup>1</sup>, Zhibin Chen<sup>2,\*</sup>, Chunyan Zheng<sup>1</sup>, ZhiChun Zhang<sup>1</sup>, YingYi  
12 Liu<sup>1</sup>, Kaining Liu<sup>2,\*</sup>, Zuhua Wang<sup>1,\*</sup>, Xiaoyan Wang<sup>1</sup>  
13  
14  
15

16  
17 1 Department of Cariology and Endodontology, Peking University School and  
18 Hospital of Stomatology & National Clinical Research Center for Oral Diseases &  
19 National Engineering Laboratory for Digital and Material Technology of Stomatology  
20 & Beijing Key Laboratory of Digital Stomatology, Beijing, China  
21  
22

23  
24 2 Department of Periodontology, Peking University School and Hospital of  
25 Stomatology & National Clinical Research Center for Oral Diseases & National  
26 Engineering Laboratory for Digital and Material Technology of Stomatology &  
27 Beijing Key Laboratory of Digital Stomatology, Beijing, China  
28  
29  
30  
31  
32

33  
34  
35 **\* Corresponding author**  
36

37 Dr. Zhibin Chen

38 Mail address: Department of Periodontology, Peking University School and Hospital  
39 of Stomatology, 22 Zhongguancun South Street, Haidian District, Beijing, 100081,  
40 China  
41  
42

43 Fax number: 86-10-62173402

44 E-mail: czb0774@sina.com  
45  
46  
47  
48  
49

50 Dr. Kaining Liu

51 Mail address: Department of Periodontology, Peking University School and Hospital  
52 of Stomatology, 22 Zhongguancun South Street, Haidian District, Beijing, 100081,  
53 China  
54  
55

56 Fax number: 86-10-62173402

57 E-mail: liukainingbjmu@163.com  
58  
59  
60

1  
2  
3  
4 Dr. Zuhua Wang

5 Mailing address: Department of Cariology and Endodontology, Peking University  
6 School and Hospital of Stomatology, 22 Zhongguancun South Street, Haidian District,  
7 Beijing, 100081, China  
8

9  
10  
11 Fax number: 86-10-62173402

12  
13 E-mail: wangzuhua@pkuss.bjmu.edu.cn  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ABSTRACT

**Introduction:** Endodontic microsurgery is a treatment of last resort for preserving natural teeth. According to radiographic evaluation, the percentage of complete healing after endodontic microsurgery is only 74.3%. The use of regenerative techniques in endodontic microsurgery for large lesions (>10 mm diameter) is therefore recommended. The most frequently used bone graft in endodontic microsurgery is anorganic bovine bone mineral (ABBM) but this only has an osteoconductive effect. Thus, when platelet-rich fibrin (PRF), a reservoir of growth factors, is used together with ABBM, it increases the regenerative effect. This study is devoted to comparing the clinical outcomes of PRF with/without ABBM as grafting biomaterials in endodontic microsurgery cases with large lesion size to provide some valuable reference data for dentists.

**Methods and analysis:** Sixteen patients who are in need of endodontic microsurgery will be recruited. The patients will be randomly assigned to one of two groups: an experimental group, treated with PRF/ABBM complex and collagen membrane, and a control group, treated with ABBM and collagen membrane. Clinical examination including percussion, mobility testing and presence/absence of sinus will be recorded at 7 days, and at 3, 6 and 12 months after endodontic microsurgery. A visual analogue scale (VAS) will be used by the patients to evaluate pain at 1, 3 and 7 days after endodontic microsurgery. Routine paralleling radiographs will be obtained before and at 3, 6 and 12 months follow-up after endodontic microsurgery. Cone-beam computed tomographic (CBCT) scans will be obtained at the 12-month follow-up. Bone formation will be evaluated according to CBCT and paralleling radiographs.

**Ethics and dissemination:** The present study received approval from the Ethics Committee of Peking University School and Hospital of Stomatology. Research data will be registered with the International Clinical Trials Registry Platform (ICTRP), ID: ChiCTR2100046684. The results will be disseminated through scientific journals.

### **Strengths and limitations of this study:**

This trial is designed as a randomised, double-blind clinical trial.

The trial will be the first clinical trial with a novel design to compare the clinical and

1  
2  
3  
4 radiographic effects of PRF/ABBM complex and ABBM on large periapical lesions  
5 (>10 mm diameter) after endodontic microsurgery.  
6

7 This study will collect longitudinal data on patients during the subsequent 12-month  
8 follow-up.  
9

10  
11 The patients with systemic disease will not be included in this research.  
12

13 **Keywords:** Platelet-rich fibrin, Endodontic microsurgery, Large lesion size,  
14 Osteoinduction, Regeneration techniques  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

With developments in equipment, instruments and biomaterials, endodontic microsurgery has become available as a treatment of last resort for cases which are no longer suitable for retreatment.<sup>1</sup> It is generally accepted that radiographic outcomes can be classified into complete healing, incomplete healing, uncertain healing and unsatisfactory healing.<sup>2,3</sup> Complete bone repair is the ideal therapeutic outcome of endodontic microsurgery, however, the percentage of complete radiographic healing after endodontic microsurgery is only 74.3%.<sup>4</sup> Thus, it is imperative to promote healing of periapical bone defects more effectively. The results of endodontic microsurgery can be influenced by several factors, especially lesion size. During the healing process, epithelial cells repopulate the wound at the highest rate which results in scar formation.<sup>5</sup> Once complete osseous regeneration of a defect cannot occur, the defect will be filled by fibrous connective tissue.<sup>6</sup> It has been demonstrated that 26% of defects radiographically larger than 10 mm result in scar formation after endodontic microsurgery.<sup>7</sup> Thus, usage of grafting materials and membrane in cases with large lesion size (>10mm diameter) is recommended.<sup>8-10</sup>

There are four types of bone grafts: autogenous grafts, allogeneic grafts, xenogeneic grafts and alloplastic materials. Autogenous grafts and allogeneic grafts are osteoinductive materials, while xenogeneic grafts and alloplastic materials are osteoconductive materials due to their lack of growth factors.<sup>11</sup> It has been reported that a combination of osteoconductive materials (e.g. anorganic bovine bone mineral (ABBM)) and growth factors results in faster and better healing of bone in endodontic microsurgery than osteoconductive materials only.<sup>12,13</sup>

PRF (platelet-rich fibrin) contains platelets, leukocytes and more than 100 types of growth factors including platelet-derived growth factor (PDGF), transforming growth factor-beta 1 (TGF- $\beta$ 1), vascular endothelial growth factor (VEGF) and bone morphogenetic protein 2 (BMP-2), which promote the proliferation and differentiation of osteoblasts.<sup>14</sup> Moreover, the presence of leukocytes is helpful for their anti-infection and immunomodulatory effects.<sup>15-17</sup> Previously, PRF has been extensively used in dentistry, including the healing of extraction sockets,<sup>18</sup> ridge

1  
2  
3  
4 preservation, <sup>19</sup> maxillary sinus augmentation and the regeneration of periodontal  
5 lesions. <sup>20-24</sup> It promotes the healing of soft tissue, and reduces postoperative pain,  
6 swelling, and the incidence of alveolar osteitis after the extraction of impacted  
7 mandibular third molars. <sup>18</sup> Compared with natural healing, horizontal and vertical  
8 dimension ridge preservation is more effective with the use of PRF. <sup>19</sup> The  
9 combination of PRF and deproteinized bovine bone mineral has been shown to  
10 increase bone formation in maxillary sinus augmentation compared with  
11 deproteinized bovine bone mineral alone. <sup>20</sup> Plenty of studies have indicated that  
12 combinations of PRF and bone grafting materials enhance periodontal regeneration in  
13 periodontal intrabony defects. <sup>21-24</sup> In a word, PRF has the potential for osseous  
14 regeneration and healing of soft tissue, especially when combined with various bone  
15 grafting materials. <sup>25</sup> It was also indicated that PRF reduces post-operative pain and  
16 infections due to the improvements in soft-tissue healing and the presence of  
17 microbial-fighting immune cells. <sup>26</sup> Hitherto, there have only been two case reports in  
18 which PRF was used together with osteoconductive bone grafts in periapical surgery  
19 in order to achieve a better healing outcome. <sup>27, 28</sup> With the exception of these two  
20 case reports, there has been no clinical research into the effects of PRF in periapical  
21 surgery.

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39 We hypothesized that PRF combined with ABBM and collagen membrane is  
40 more effective than using only ABBM and collagen membrane in endodontic  
41 microsurgery. The hypothesis will be tested in the present double-masked randomised  
42 controlled clinical trial, the design of which is described below.

## 43 44 45 46 47 48 49 **METHODS AND ANALYSIS**

50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The study is a prospective, single-centre randomised controlled trial. It had been approved by the Ethics Committee of Peking University School and Hospital of Stomatology (PKUSSIRB-202059179). Research procedures including assessments, interventions and follow-ups will be carried out in Peking University School and Hospital of Stomatology (Beijing, China). This study has been registered with the registry of ICTRP (ID: ChiCTR2100046684). The main objective of this randomised



1  
2  
3  
4 controlled clinical trial is to compare and evaluate the clinical effects of PRF with or  
5 without combination with ABBM in endodontic microsurgery cases with large lesion  
6 size (>10 mm diameter). The primary hypothesis is that healing of periapical lesions  
7 will be better in the PRF/ABBM complex group.  
8  
9  
10

### 11 12 13 **Inclusion criteria**

14  
15 Patients attending the Department of Cariology and Endodontology for routine  
16 planned endodontic microsurgery will be evaluated for inclusion in this clinical trial.  
17 The age of patients to be recruited will range from 18 to 65 years. Patients will have  
18 received periodontal treatment before endodontic microsurgery. Only single-rooted  
19 teeth will be included in the study, and the periapical lesions should be classified as  
20 large periapical lesions (>10mm diameter) according to cone-beam computed  
21 tomographic (CBCT) evaluation.  
22  
23  
24  
25  
26  
27  
28

### 29 **Exclusion criteria**

- 30 1. Smokers;
  - 31 2. Pregnant women;
  - 32 3. Patients with systemic diseases;
  - 33 4. Re-surgery;
  - 34 5. Unqualified coronal restoration;
  - 35 6. Teeth with deep periodontal pockets (probing depth  $\geq 5$ mm).
- 36  
37  
38  
39  
40  
41  
42

### 43 **Recruitment**

44 Patients who are willing to participate in this study will be recruited from the  
45 Department of Cariology and Endodontology, Peking University School and Hospital  
46 of Stomatology. The necessity of endodontic microsurgery and collecting blood for  
47 PRF/ABBM complex will be explained to the participants. A signed informed consent  
48 form will be obtained and preserved confidentially in the cabinet. The procedures of  
49 this clinical trial are shown in Figure 1.  
50  
51  
52  
53  
54  
55

### 56 **Groups, randomisation and blinding**

57 An experienced endodontist will perform the examination, diagnosis and assessment  
58 procedures after clinical and radiographic examinations. The sequence and allocation  
59  
60

1  
2  
3  
4 will be performed by a professor alone with opaque envelopes. The bone grafting  
5 material of the experimental group will be a PRF/ABBM composite, while the control  
6 group will receive ABBM only.  
7  
8

### 9 **Interventions**

10  
11 All enrolled patients will be randomly divided into two groups after examination. The  
12 endodontic microsurgery will be performed by the same experienced endodontist  
13 using an endodontic microscope (F40, Leica Microsystems Ltd, Wetzlar, Germany).  
14 The procedures and principles of the endodontic microsurgeries will follow the  
15 guidelines proposed by Prof. Kim.<sup>29</sup> A vertical and a horizontal incision will be used  
16 to reflect the flap. Peri-radicular curettage will be performed after reaching the  
17 periapical lesion. After 3mm of the root apex is resected, retro-preparation and  
18 retro-filling with iRoot BP (Innovative BioCeramix Inc., Burnaby, BC, Canada) will  
19 be performed. In the experimental group, after peri-radicular curettage, whole blood  
20 (10 mL) will be collected and centrifuged at 960 rpm (Medical centrifuge Auto V1,  
21 JM Instrument, Beijing, China) for 2.8 minutes. The upper layer consisting of liquid  
22 PRF will be mixed with ABBM (Heal-all, ZH-Bio, Yantai, China) evenly. ABBM is a  
23 category of xenograft which has only an osteoconductive effect. The periapical  
24 defects will be filled with PRF/ABBM complex in the experimental group while the  
25 periapical defects will be filled with ABBM only in the control group. An absorbable  
26 collagen membrane (Heal-all, ZH-Bio, Yantai, China) will be applied in both groups,  
27 then the flap will be repositioned with 6-0 sutures. Amoxicillin and 0.2%  
28 chlorhexidine gluconate rinse will be prescribed to prevent postoperative infection.  
29 Sutures will be removed 5 days after the endodontic microsurgery.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Examination**

#### 49 **Baseline examination**

50  
51 Before treatment, all participants will be examined carefully by a calibrated examiner.  
52  
53 Clinical examination including percussion and mobility testing and presence/absence  
54 of sinus will be recorded simultaneously. Preoperative paralleling radiographs and  
55  
56 CBCT scans will be obtained for each participant.  
57  
58  
59

#### 60 **Examination during the follow-up period**

Clinical examination including percussion, mobility testing and presence/absence of sinus will be performed at 7 days, 3 months, 6 months and 12 months after the endodontic microsurgery. In addition, a visual analogue scale (VAS) will be recorded at 1 day, 3 days and 7 days after the endodontic microsurgery for the evaluation of postoperative pain. Paralleling radiographs will be obtained at 3 months, 6 months and 12 months. CBCT scans will be performed at the 12-month follow-up. The grouping and the treatment plan will be confidential to the examiners. The primary parameter of the present clinical trial is radiographic bone regeneration in the area of the periapical defect. The paralleling radiographs and CBCT scans will be evaluated both before and after microsurgery. Bone regeneration in periapical osseous defects will be evaluated according to the radiopacity scoring scale of paralleling radiographs by three independent blinded and calibrated examiners at the 3-month, 6-month and 12-month follow-ups after the microsurgery and compared with the paralleling radiograph after microsurgery immediately. According to a previous study,<sup>30</sup> the change in the volume of the periapical defect is the evaluation index of the radiopacity scoring scale. CBCT data before and 12 months after microsurgery will be processed using medical image processing software (MIMICS, Materialise, Leuven, Belgium) to evaluate the changes of volume and density of the periapical defect. The data of the clinical trial will be input and kept in a specific computer and a locked cabinet by two designated member of staffs. The secondary parameters of this clinical trial include percussion, mobility testing and presence/absence of sinus. The VAS scores are also secondary parameters. All the data will be recorded and imputed in the computer simultaneously. Due to lack of data monitoring committee in our hospital, the data will be kept in the cabinet by two different researchers to make sure the accuracy and completeness of the data. An independent inspector will review the incoming data every 3 months. There will be no harms caused by the trial.

### **Sample size**

The sample size of this clinical trial is determined by the following formula:

$$N1 = N2 = 2 \left[ \frac{\sigma(Z_{\alpha/2} + Z_{\beta})}{\delta} \right]^2$$

1  
2  
3  
4 According to the data of a published clinical trial, which is about bone grafting in  
5 periapical osseous defects,<sup>30</sup> the  $\sigma/\delta$  is around 0.49. The inspection level ( $\alpha$ ) is set to  
6 0.05, and the power is set to 0.9. For bilateral tests, the required sample size in each  
7 group is six. Considering a missed follow-up rate of 20%, the sample size should be  
8 7.2. Consequently 16 participants will be needed.

### 13 **Statistical analysis**

14  
15 Data will be analysed using SPSS software (SPSS, Inc, Chicago, IL, USA). Statistical  
16 significance will be accepted for  $P$  values lower than 0.05. Normality and variance  
17 equality will be analysed using the Shapiro-Wilk test and the Levene variance  
18 homogeneity test, respectively. Normally-distributed data will be shown as mean  $\pm$   
19 standard deviation, while non-normally distributed data will be shown as median  
20 (lower to upper quartile). Student's  $t$ -test will be used to compare the difference  
21 between the two groups for the data with both normality and variance equality.  
22  
23 Otherwise, the Mann-Whitney  $U$  test will be used.

### 31 **Withdrawal**

32  
33 The patients have the right to withdraw from this clinical trial without any reason at  
34 any point during the treatment. Follow-up treatment will not be affected by the  
35 withdrawal.

### 38 **Dissemination of results**

39  
40 The results of this clinical trial will be registered at the International Clinical Trials  
41 Registry Platform (ICTRP). In addition, the results will be published in a  
42 peer-reviewed journal.

## 48 **DISCUSSION**

49  
50 When PRF is used together with ABBM, it increases the regenerative effect of  
51 osseous tissue,<sup>31, 32</sup> because ABBM only has an osteoconductive effect and  
52 osteoinduction is induced due to the growth factors in PRF. In a histological study,  
53 bone regenerative effects of PRF-TCP, rhBMP-2-coated TCP and TCP alone were  
54 compared, and the results showed that PRF-TCP resulted in more rapid bone healing  
55 compared to the other two groups.<sup>12</sup> The antibacterial and anti-inflammatory effects  
56  
57  
58  
59  
60

1  
2  
3  
4 of PRF also promoted tissue healing.<sup>14</sup> Although PRF has many advantages,  
5 traditional PRF is not liquid, and it is challenging to mix PRF and ABBM evenly.  
6 Thus, in previous studies,<sup>33-35</sup> the gelatinous PRF had to be minced and then mixed  
7 with ABBM, which is time-consuming. Exposing alveolar bone to air could result in  
8 bone resorption, and a long duration of surgery is not favourable.<sup>36</sup> Therefore, our  
9 group developed a new technique to obtain a type of PRF/ABBM complex and thus  
10 avoid the need to mince the PRF.<sup>23, 24</sup> Additionally, PRF/ABBM complex as a whole  
11 had better applicability than granular ABBM, and could significantly reduce the time  
12 required for bone grafting.<sup>24</sup> The complex together with a collagen membrane has  
13 been demonstrated to result in enhanced gains in attachment level compared to  
14 ABBM alone with a collagen membrane, indicating improved periodontal  
15 regeneration.<sup>24</sup>

16  
17 To date there is still a lack of clinical trials investigating the osseous regenerative  
18 effect of PRF/bone grafting material composites in endodontic microsurgery. This  
19 randomised controlled trial is devoted to the evaluation of the clinical outcomes of the  
20 application of a PRF/ABBM complex as a grafting biomaterial in endodontic  
21 microsurgery cases with large lesion size, in the hope of providing some scientific  
22 evidence to support endodontic microsurgeries for dentists.

### 23 **Ethics and dissemination**

24 Ethical approval had been approved by the Ethics Committee of Peking University  
25 School and Hospital of Stomatology (PKUSSIRB-202059179). The data of the  
26 clinical trial will be input and kept in a specific computer and a locked cabinet by two  
27 designated member of staffs. The results will be published in a peer-reviewed journal.  
28 Research data will be registered with the International Clinical Trials Registry  
29 Platform (ICTRP), ID: ChiCTR2100046684.

### 30 **Trial status**

31 The trial has been registered at the International Clinical Trials Registry Platform  
32 (ICTRP). The identifier number is ChiCTR2100046684. Recruitment will begin in  
33 June 2021 and will end in June 2023.

### 34 **Contributors**

1  
2  
3  
4 The study concept was proposed by ZW, KL, ZC and BH. The manuscript was  
5 drafted by BH and KL. CZ and ZZ revised the part on randomisation. YW and YL  
6 calculated the sample size. ZW, XW and KL revised the manuscript finally. All  
7 authors have agreed with the final version of the manuscript.  
8  
9

### 10 11 **Funding**

12  
13 This work was supported by grants from the Program for New Clinical Techniques  
14 and Therapies of Peking University School and Hospital of Stomatology  
15 (PKUSSNCT-17B02 , PKUSSNCT-20A04 and PKUSSNCT-20B13).  
16  
17

### 18 19 **Competing interests**

20  
21 None declared.  
22

### 23 24 **Patient consent for publication**

25  
26 Not required.  
27

### 28 29 **Provenance and peer review**

30  
31 Not commissioned; externally peer-reviewed.  
32

### 33 34 **Open access**

35 This is an open access article distributed in accordance with the Creative Commons  
36 Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to  
37 distribute, remix, adapt, build upon this work non-commercially, and license their  
38 derivative works on different terms, provided the original work is properly cited,  
39 appropriate credit is given, any changes made indicated, and the use is  
40 non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 53 **References**

- 54 1 Monaghan L, Jadun S, Darcey J. Endodontic microsurgery. Part one: diagnosis,  
55 patient selection and prognoses. *Brit Dent J* 2019;226:940-8.  
56  
57 2 Rud J, Andreasen JO, Jensen JE. Radiographic criteria for the assessment of healing  
58 after endodontic surgery. *Int J Oral Surg* 1972;1:195-214.  
59  
60

- 1  
2  
3  
4 3 Molven O, Halse A, Grung B. Observer strategy and the radiographic classification  
5 of healing after endodontic surgery. *Int J Oral Maxillofac Surg* 1987;16:432-9.
- 6  
7  
8 4 Wang ZH, Zhang MM, Wang J, *et al.* Outcomes of Endodontic Microsurgery Using  
9 a Microscope and Mineral Trioxide Aggregate: A Prospective Cohort Study. *J Endod*  
10 2017;43:694-8.
- 11  
12  
13 5 Tobón SI, Arismendi JA, Marín ML, *et al.* Comparison between a conventional  
14 technique and two bone regeneration techniques in periradicular surgery. *Int Endod J*  
15 2002;35:635-41.
- 16  
17  
18 6 Chaturvedy V, Chaturvedy S. Regenerative therapy as an adjunct to periapical  
19 surgery: a case report. *Int J Clin Pediatr Dent* 2012;5:75-7.
- 20  
21  
22 7 Kim S, Kratchman S. *Microsurgery in Endodontics*. Wiley-Blackwell 2017.
- 23  
24  
25 8 Deng Y, Zhu X, Yang J, *et al.* The Effect of Regeneration Techniques on Periapical  
26 Surgery With Different Protocols for Different Lesion Types: A Meta-Analysis. *J*  
27 *Oral Maxillofac Surg* 2016;74:239-46.
- 28  
29  
30 9 Sánchez-Torres A, Sánchez-Garcés MÁ, Gay-Escoda C. Materials and prognostic  
31 factors of bone regeneration in periapical surgery: a systematic review. *Med Oral*  
32 *Patol Oral Cir Bucal* 2014;19: e419-25.
- 33  
34  
35 10 Lin YC, Lee YY, Ho YC, *et al.* Treatment of large apical lesions with mucosal  
36 fenestration: a clinical study with long-term evaluation. *J Endod* 2015;41:563-7.
- 37  
38  
39 11 Chen FM, Liu X. Advancing biomaterials of human origin for tissue engineering.  
40 *Prog Polym Sci* 2016;53:86-168.
- 41  
42  
43 12 Kim BJ, Kwon TK, Baek HS, *et al.* A comparative study of the effectiveness of  
44 sinus bone grafting with recombinant human bone morphogenetic protein 2-coated  
45 tricalcium phosphate and platelet-rich fibrin-mixed tricalcium phosphate in rabbits.  
46 *Oral Surg Oral Med Oral Pathol Oral Radiol* 2012;113:583-92.
- 47  
48  
49 13 Taschieri S, Rosano G, Weinstein T, *et al.* Treatment of through-and-through bone  
50 lesion using autologous growth factors and xenogeneic bone graft: a case report. *Oral*  
51 *Maxillofac Surg* 2012;16:57-64.
- 52  
53  
54 14 Miron RJ, Zucchelli G, Pikos MA, *et al.* Use of platelet-rich fibrin in regenerative  
55 dentistry: a systematic review. *Clin Oral Investig* 2017;21:1913-27.
- 56  
57  
58  
59  
60

1  
2  
3  
4 15 Bielecki T, Dohan ED, Everts PA, *et al.* The role of leukocytes from  
5 L-PRP/L-PRF in wound healing and immune defense: new perspectives. *Curr Pharm*  
6 *Biotechnol* 2012,13:1153-62.

7  
8  
9 16 Zhang J, Yin C, Zhao Q, *et al.* Anti-inflammation effects of injectable platelet-rich  
10 fibrin via macrophages and dendritic cells. *J Biomed Mater Res A* 2020,108:61-8.

11  
12  
13 17 Jasmine S, Thangavelu A, Janarthanan K, *et al.* Antimicrobial and antibiofilm  
14 potential of injectable platelet rich fibrin-a second-generation platelet  
15 concentrate-against biofilm producing oral staphylococcus isolates. *Saudi J Biol Sci*  
16 2020,27:41-6.

17  
18  
19 18 Daugela P, Grimuta V, Sakavicius D, *et al.* Influence of leukocyte- and  
20 platelet-rich fibrin (L-PRF) on the outcomes of impacted mandibular third molar  
21 removal surgery: A split-mouth randomized clinical trial. *Quintessence Int*  
22 2018,49:377-88.

23  
24  
25 19 Temmerman A, Vandessel J, Castro A, *et al.* The use of leucocyte and platelet-rich  
26 fibrin in socket management and ridge preservation: a split-mouth, randomized,  
27 controlled clinical trial. *J Clin Periodontol* 2016,43:990-9.

28  
29  
30 20 Pichotano EC, de Molon RS, de Souza RV, *et al.* Evaluation of L-PRF combined  
31 with deproteinized bovine bone mineral for early implant placement after maxillary  
32 sinus augmentation: A randomized clinical trial. *Clin Implant Dent Relat Res*  
33 2019,21:253-62.

34  
35  
36 21 Bodhare GH, Kolte AP, Kolte RA, *et al.* Clinical and radiographic evaluation and  
37 comparison of bioactive bone alloplast morsels when used alone and in combination  
38 with platelet-rich fibrin in the treatment of periodontal intrabony defects-A  
39 randomized controlled trial. *J Periodontol* 2019,90:584-94.

40  
41  
42 22 Pradeep AR, Bajaj P, Rao NS, *et al.* Platelet-Rich Fibrin Combined With a Porous  
43 Hydroxyapatite Graft for the Treatment of 3-Wall Intrabony Defects in Chronic  
44 Periodontitis: A Randomized Controlled Clinical Trial. *J Periodontol*  
45 2017,88:1288-96.

46  
47  
48 23 Liu K, Huang Z, Chen Z, *et al.* Treating periodontal intrabony defects using guided  
49 tissue regeneration and Bio-Oss® with platelet-rich fibrin: study protocol for a  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 self-controlled trial. *Clin Trials Orthop Disord* 2020,5:9-13.

5  
6 24 Liu K, Huang Z, Chen Z, *et al.* Treatment of periodontal intrabony defects using  
7 bovine porous bone mineral and guided tissue regeneration with/without platelet-rich  
8 fibrin: a randomized controlled clinical trial. *J Periodontol* 2021, Online ahead of  
9 print. Doi: 10.1002/JPER.20-0860.

10  
11  
12  
13 25 Varghese MP, Manuel S, Kumar LKS. Potential for Osseous Regeneration of  
14 Platelet-Rich Fibrin-A Comparative Study in Mandibular Third Molar Impaction  
15 Sockets. *J Oral Maxillofac Surg* 2017,75:1322-9.

16  
17  
18  
19 26 Bilginaylar K, Uyanik LO. Evaluation of the effects of platelet-rich fibrin and  
20 piezosurgery on outcomes after removal of impacted mandibular third molars. *Br J*  
21 *Oral Maxillofac Surg* 2016,54:629-33.

22  
23  
24  
25 27 Uppada UK, Kalakonda B, Koppolu P, *et al.* Combination of hydroxyapatite,  
26 platelet rich fibrin and amnion membrane as a novel therapeutic option in regenerative  
27 periapical endodontic surgery: Case series. *Int J Surg Case Rep* 2017,37:139-44.

28  
29  
30  
31 28 Hiremath H, Motiwala T, Jain P, *et al.* Use of second-generation platelet  
32 concentrate (platelet-rich fibrin) and hydroxyapatite in the management of large  
33 periapical inflammatory lesion: a computed tomography scan analysis. *Indian J Dent*  
34 *Res* 2014,25:517-20.

35  
36  
37  
38 29 Kim S, Kratchman S. Modern Endodontic Surgery Concepts and Practice: A  
39 Review. *J Endod* 2006,32:601-23.

40  
41  
42  
43 30 Nakkeeran KP, Saravanan K, Babu P, *et al.* Evaluation of bone regeneration in  
44 periapical osseous defects with and without platelet rich plasma, combined calcium  
45 sulfate and autologous bone graft - A comparative study. *J Stomatol Oral Maxillofac*  
46 *Surg* 2019,120:196-202.

47  
48  
49  
50 31 Kim NR, Lim BS, Park HC, *et al.* Effects of N-acetylcysteine on TEGDMA- and  
51 HEMA-induced suppression of osteogenic differentiation of human osteosarcoma  
52 MG63 cells. *J Biomed Mater Res B Appl Biomater* 2011,98B:300-7.

53  
54  
55  
56 32 Jayalakshmi KB, Agarwal S, Singh MP, *et al.* Platelet-Rich Fibrin with  $\beta$   
57 -Tricalcium Phosphate-A Noval Approach for Bone Augmentation in Chronic  
58 Periapical Lesion: A Case Report. *Case Rep Dent* 2012,2012:902858.  
59  
60

1  
2  
3  
4 33 Cortellini S, Castro AB, Temmerman A, *et al.* Leucocyte- and platelet-rich fibrin  
5 block for bone augmentation procedure: A proof-of-concept study. *J Clin Periodontol*  
6 2018,45:624-34.  
7

8  
9 34 Lei L, Yu Y, Ke T, *et al.* The Application of Three-Dimensional Printing Model  
10 and Platelet-Rich Fibrin Technology in Guided Tissue Regeneration Surgery for  
11 Severe Bone Defects. *J Oral Implantol* 2019,45:35-43.  
12

13  
14 35 Sezgin Y, Uraz A, Taner IL, *et al.* Effects of platelet-rich fibrin on healing of  
15 intra-bony defects treated with anorganic bovine bone mineral. *Braz Oral Res*  
16 2017,31:e15.  
17

18  
19 36 Fickl S, Kerschull M, Schupbach P, *et al.* Bone loss after full-thickness and  
20 partial-thickness flap elevation. *J Clin Periodontol* 2011,38:157-62.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 **Figure Legend:**

42 **Figure 1** The flow chart of this clinical research  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 The flow chart of this clinical research  
189x175mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	11
Funding	4	Sources and types of financial, material, and other Support	12
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 2, 11
	5b	Name and contact information for the trial sponsor	12
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for Undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5, 6
	6b	Explanation for choice of comparators	6
Objectives	7	Specific objectives or hypotheses	6

1				
2	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
3				
4				
5				
6				
7				
8	<b>Methods: Participants, interventions, and outcomes</b>			
9				
10	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6, 7
11				
12				
13				
14	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
15				
16				
17				
18				
19	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8
20				
21				
22		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
23				
24				
25				
26				
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	N/A
29				
30				
31				
32		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
33				
34				
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8, 9
36				
37				
38				
39				
40				
41				
42				
43				
44				
45	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7, 8, 9
46				
47				
48				
49	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	9, 10
50				
51				
52				
53				
54	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7
55				
56				

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

1				
2	Sequence	16a	Method of generating the allocation sequence	7, 8
3	generation		(eg, computer-generated random numbers), and list of	
4			any factors for stratification. To reduce predictability of a	
5			random sequence, details of any planned restriction (eg, blocking)	
6			should be provided in a separate document that is unavailable to	
7			those who enrol participants or assign interventions	
8				
9				
10	Allocation	16b	Mechanism of implementing the allocation sequence	7, 8
11	concealment		(eg, central telephone; sequentially numbered, opaque, sealed	
12	mechanism		envelopes), describing any steps to conceal the sequence until	
13			interventions are assigned	
14				
15	Implementation	16c	Who will generate the allocation sequence,	7, 8
16			who will enrol participants, and who will assign participants to	
17			interventions	
18				
19				
20	Blinding	17a	Who will be blinded after assignment to interventions	8, 9
21	(masking)		(eg, trial participants, care providers, outcome assessors,	
22			data analysts), and how	
23				
24				
25		17b	If blinded, circumstances under which unblinding	N/A
26			is permissible, and procedure for revealing a participant's	
27			allocated intervention during the trial	
28				
29	<b>Methods: Data collection, management, and analysis</b>			
30				
31	Data collection	18a	Plans for assessment and collection of outcome, baseline	8, 9
32	methods		and other trial data, including any related processes to	
33			promote data quality (eg, duplicate measurements, training of	
34			assessors) and a description of study instruments	
35			(eg, questionnaires, laboratory tests) along with their	
36			reliability and validity, if known. Reference to where data	
37			collection forms can be found, if not in the protocol	
38				
39				
40				
41		18b	Plans to promote participant retention and complete	9, 10
42			follow-up, including list of any outcome data to be collected	
43			for participants who discontinue or deviate from intervention protocols	
44				
45	Data	19	Plans for data entry, coding, security, and storage,	9
46	management		including any related processes to promote data quality	
47			(eg, double data entry; range checks for data values). Reference to	
48			where details of data management procedures can be found, if not in	
49			the protocol	
50				
51				
52	Statistical	20a	Statistical methods for analysing primary and secondary	10
53	methods		outcomes. Reference to where other details of the statistical	
54			analysis plan can be found, if not in the protocol	
55				
56		20b	Methods for any additional analyses (eg, subgroup and	N/A
57			adjusted analyses)	
58				
59				
60				

1				
2		20c	Definition of analysis population relating to protocol	N/A
3			non-adherence (eg, as randomised analysis), and any	
4			statistical methods to handle missing data (eg, multiple imputation)	
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

### Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	9
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	9
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	9

### Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	11
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	N/A
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	11
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	12
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	11

1				
2	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for	N/A
3	post-trial care		compensation to those who suffer harm from trial participation	
4				
5	Dissemination	31a	Plans for investigators and sponsor to communicate trial	11
6	policy		results to participants, healthcare professionals, the public,	
7			and other relevant groups (eg, via publication, reporting in	
8			results databases, or other data sharing arrangements),	
9			including any publication restrictions	
10				
11		31b	Authorship eligibility guidelines and any intended use of	N/A
12			professional writers	
13				
14		31c	Plans, if any, for granting public access to the full protocol,	N/A
15			participant-level dataset, and statistical code	
16				
17				
18				
19	<b>Appendices</b>			
20				
21	Informed consent	32	Model consent form and other related documentation	Additional file
22	materials		given to participants and authorised surrogates	
23				
24	Biological	33	Plans for collection, laboratory evaluation, and storage	N/A
25	specimens		Of biological specimens for genetic or molecular analysis in the	
26			current trial and for future use in ancillary studies, if applicable	
27				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.



# BMJ Open

## Platelet-rich fibrin/anorganic bovine bone mineral complex as grafting materials in endodontic microsurgery with a large lesion size: study protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057068.R1
Article Type:	Protocol
Date Submitted by the Author:	20-Jan-2022
Complete List of Authors:	Han, Bing; Peking University School of Stomatology, Department of Cariology and Endodontology Wang, Yuhan; Peking University School of Stomatology, Department of Cariology and Endodontology Chen, Zhibin; Peking University School of Stomatology, Department of Periodontology Zheng, Chunyan; Peking University School of Stomatology, Department of Cariology and Endodontology Zhang, Zhichun; Peking University School of Stomatology, Department of Cariology and Endodontology Liu, Yingyi; Peking University School of Stomatology, Department of Cariology and Endodontology Liu, Kaining; Peking University School of Stomatology, Department of Periodontology Wang, Zuhua; Peking University School of Stomatology, Department of Cariology and Endodontology Wang, Xiaoyan; Peking University School of Stomatology, Department of Cariology and Endodontology
<b>Primary Subject Heading</b>:	Dentistry and oral medicine
Secondary Subject Heading:	Dentistry and oral medicine
Keywords:	Clinical trials < THERAPEUTICS, ORAL MEDICINE, ORAL & MAXILLOFACIAL SURGERY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Platelet-rich fibrin/anorganic bovine bone mineral complex as grafting materials**  
5 **in endodontic microsurgery with a large lesion size: study protocol for a**  
6 **randomised controlled trial**  
7  
8  
9

10  
11 Bing Han<sup>1</sup>, Yuhan Wang<sup>1</sup>, Zhibin Chen<sup>2,\*</sup>, Chunyan Zheng<sup>1</sup>, ZhiChun Zhang<sup>1</sup>,  
12 YingYi Liu<sup>1</sup>, Kaining Liu<sup>2,\*</sup>, Zuhua Wang<sup>1,\*</sup>, Xiaoyan Wang<sup>1</sup>  
13  
14  
15

16  
17 1 Department of Cariology and Endodontology, Peking University School and  
18 Hospital of Stomatology & National Clinical Research Center for Oral Diseases &  
19 National Engineering Laboratory for Digital and Material Technology of Stomatology  
20 & Beijing Key Laboratory of Digital Stomatology, Beijing, China  
21  
22

23  
24 2 Department of Periodontology, Peking University School and Hospital of  
25 Stomatology & National Clinical Research Center for Oral Diseases & National  
26 Engineering Laboratory for Digital and Material Technology of Stomatology &  
27 Beijing Key Laboratory of Digital Stomatology, Beijing, China  
28  
29  
30  
31  
32

33  
34  
35 **\* Corresponding author**

36 Dr. Zhibin Chen

37  
38 Mail address: Department of Periodontology, Peking University School and Hospital  
39 of Stomatology, 22 Zhongguancun South Street, Haidian District, Beijing, 100081,  
40  
41  
42 China  
43

44 Fax number: 86-10-62173402

45  
46 E-mail: czb0774@sina.com  
47  
48  
49

50 Dr. Kaining Liu

51  
52 Mail address: Department of Periodontology, Peking University School and Hospital  
53 of Stomatology, 22 Zhongguancun South Street, Haidian District, Beijing, 100081,  
54  
55  
56 China  
57

58 Fax number: 86-10-62173402

59  
60 E-mail: liukainingbjmu@163.com

1  
2  
3  
4 Dr. Zuhua Wang

5 Mailing address: Department of Cariology and Endodontology, Peking University  
6 School and Hospital of Stomatology, 22 Zhongguancun South Street, Haidian District,  
7 Beijing, 100081, China  
8

9  
10  
11 Fax number: 86-10-62173402

12  
13 E-mail: wangzuhua@pkuss.bjmu.edu.cn  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ABSTRACT

**Introduction:** Endodontic microsurgery is a treatment of last resort for preserving natural teeth. According to radiographic evaluation, the percentage of complete healing after endodontic microsurgery is only 74.3%. The use of regenerative techniques in endodontic microsurgery for large lesions (>10 mm diameter) is therefore recommended. The most frequently used bone graft in endodontic microsurgery is anorganic bovine bone mineral (ABBM) but this only has an osteoconductive effect. Thus, when platelet-rich fibrin (PRF), a reservoir of growth factors, is used together with ABBM, it increases the regenerative effect. This study is devoted to comparing the clinical outcomes of PRF with/without ABBM as grafting biomaterials in endodontic microsurgery cases with large lesion size to provide some valuable reference data for dentists.

**Methods and analysis:** Sixteen patients who are in need of endodontic microsurgery will be recruited. The patients will be randomly assigned to one of two groups: an experimental group, treated with PRF/ABBM complex and collagen membrane, and a control group, treated with ABBM and collagen membrane. Clinical examination including percussion, mobility testing and presence/absence of sinus will be recorded at 7 days, and at 3, 6 and 12 months after endodontic microsurgery. A visual analogue scale (VAS) will be used by the patients to evaluate pain at 1, 3 and 7 days after endodontic microsurgery. Routine paralleling radiographs will be obtained before and at 3, 6 and 12 months follow-up after endodontic microsurgery. Cone-beam computed tomographic (CBCT) scans will be obtained at the 12-month follow-up. Bone formation will be evaluated according to CBCT and paralleling radiographs. The study execute time including follow-ups last from June 1<sup>st</sup> 2021 to December 31<sup>st</sup> 2024.

**Ethics and dissemination:** The present study received approval from the Ethics Committee of Peking University School and Hospital of Stomatology. Research data will be registered with the International Clinical Trials Registry Platform (ICTRP), ID: ChiCTR2100046684. The results will be disseminated through scientific journals.

**Strengths and limitations of this study:**

1  
2  
3  
4 This trial is designed as a randomised, double-blind clinical trial.

5  
6 The trial will be the first clinical trial with a novel design to compare the clinical and  
7  
8 radiographic effects of PRF/ABBM complex and ABBM on large periapical lesions  
9  
10 (>10 mm diameter) after endodontic microsurgery.

11  
12 This study will collect longitudinal data on patients during the subsequent 12-month  
13  
14 follow-up.

15  
16 The patients with systemic disease will not be included in this research.

17  
18 **Keywords:** Platelet-rich fibrin, Endodontic microsurgery, Large lesion size,  
19  
20 Osteoinduction, Regeneration techniques  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

With developments in equipment, instruments and biomaterials, endodontic microsurgery has become available as a treatment of last resort for cases which are no longer suitable for retreatment.<sup>1</sup> It is generally accepted that radiographic outcomes can be classified into complete healing, incomplete healing, uncertain healing and unsatisfactory healing.<sup>2,3</sup> Complete bone repair is the ideal therapeutic outcome of endodontic microsurgery, however, the percentage of complete radiographic healing after endodontic microsurgery is only 74.3%.<sup>4</sup> Thus, it is imperative to promote healing of periapical bone defects more effectively. The results of endodontic microsurgery can be influenced by several factors, especially lesion size<sup>5,6</sup>. During the healing process, epithelial cells repopulate the wound at the highest rate which results in scar formation.<sup>7</sup> Once complete osseous regeneration of a defect cannot occur, the defect will be filled by fibrous connective tissue.<sup>8</sup> It has been demonstrated that 26% of defects radiographically larger than 10 mm result in scar formation after endodontic microsurgery.<sup>9</sup> Thus, usage of grafting materials and membrane in cases with large lesion size (>10mm diameter) is recommended.<sup>5,6,10</sup>

There are four types of bone grafts: autogenous grafts, allogeneic grafts, xenogeneic grafts and alloplastic materials. Autogenous grafts and allogeneic grafts are osteoinductive materials, while xenogeneic grafts and alloplastic materials are osteoconductive materials due to their lack of growth factors.<sup>11</sup> It has been reported that a combination of osteoconductive materials (e.g. anorganic bovine bone mineral (ABBM)) and growth factors results in faster and better healing of bone in endodontic microsurgery than osteoconductive materials only.<sup>12,13</sup>

PRF (platelet-rich fibrin) contains platelets, leukocytes and more than 100 types of growth factors including platelet-derived growth factor (PDGF), transforming growth factor-beta 1 (TGF- $\beta$ 1), vascular endothelial growth factor (VEGF) and bone morphogenetic protein 2 (BMP-2), which promote the proliferation and differentiation of osteoblasts.<sup>14</sup> Moreover, the presence of leukocytes is helpful for their anti-infection and immunomodulatory effects.<sup>15-17</sup> Previously, PRF has been extensively used in dentistry, including the healing of extraction sockets,<sup>18</sup> ridge

1  
2  
3  
4 preservation, <sup>19</sup> maxillary sinus augmentation and the regeneration of periodontal  
5 lesions. <sup>20-24</sup> It promotes the healing of soft tissue, and reduces postoperative pain,  
6 swelling, and the incidence of alveolar osteitis after the extraction of impacted  
7 mandibular third molars. <sup>18</sup> Compared with natural healing, horizontal and vertical  
8 dimension ridge preservation is more effective with the use of PRF. <sup>19</sup> The  
9 combination of PRF and deproteinized bovine bone mineral has been shown to  
10 increase bone formation in maxillary sinus augmentation compared with  
11 deproteinized bovine bone mineral alone. <sup>20</sup> Plenty of studies have indicated that  
12 combinations of PRF and bone grafting materials enhance periodontal regeneration in  
13 periodontal intrabony defects. <sup>21-24</sup> In a word, PRF has the potential for osseous  
14 regeneration and healing of soft tissue, especially when combined with various bone  
15 grafting materials. <sup>25</sup> It was also indicated that PRF reduces post-operative pain and  
16 infections due to the improvements in soft-tissue healing and the presence of  
17 microbial-fighting immune cells. <sup>26</sup> Hitherto, there have only been two case reports in  
18 which PRF was used together with osteoconductive bone grafts in periapical surgery  
19 in order to achieve a better healing outcome. <sup>27, 28</sup> With the exception of these two  
20 case reports, there has been no clinical research into the effects of PRF in periapical  
21 surgery.

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39 We hypothesized that PRF combined with ABBM and collagen membrane is  
40 more effective than using only ABBM and collagen membrane in endodontic  
41 microsurgery. The hypothesis will be tested in the present double-masked randomised  
42 controlled clinical trial, the design of which is described below.

## 43 44 45 46 47 48 49 **METHODS AND ANALYSIS**

50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The study is a prospective, single-centre randomised controlled trial. It had been approved by the Ethics Committee of Peking University School and Hospital of Stomatology (PKUSSIRB-202059179). Research procedures including assessments, interventions and follow-ups will be carried out in Peking University School and Hospital of Stomatology (Beijing, China). This study has been registered with the registry of ICTRP (ID: ChiCTR2100046684). The main objective of this randomised

1  
2  
3  
4 controlled clinical trial is to compare and evaluate the clinical effects of PRF with or  
5 without combination with ABBM in endodontic microsurgery cases with large lesion  
6 size (>10 mm diameter). The primary hypothesis is that healing of periapical lesions  
7 will be better in the PRF/ABBM complex group.  
8  
9  
10

### 11 12 13 **Inclusion criteria**

14  
15 Patients attending the Department of Cariology and Endodontology for routine  
16 planned endodontic microsurgery will be evaluated for inclusion in this clinical trial.  
17 The age of patients to be recruited will range from 18 to 65 years. Patients will have  
18 received periodontal treatment before endodontic microsurgery. Only single-rooted  
19 teeth will be included in the study, and the periapical lesions should be classified as  
20 large periapical lesions (>10mm diameter) according to cone-beam computed  
21 tomographic (CBCT) evaluation.  
22  
23  
24  
25  
26  
27  
28

### 29 **Exclusion criteria**

- 30 1. Smokers;
- 31 2. Pregnant women;
- 32 3. Patients with systemic diseases;
- 33 4. Re-surgery;
- 34 5. Unqualified coronal restoration;
- 35 6. Teeth with deep periodontal pockets (probing depth  $\geq 5$ mm).
- 36  
37  
38  
39  
40  
41

### 42 **Recruitment**

43  
44 Patients who are willing to participate in this study will be recruited from the  
45 Department of Cariology and Endodontology, Peking University School and Hospital  
46 of Stomatology. The necessity of endodontic microsurgery and collecting blood for  
47 PRF/ABBM complex will be explained to the participants. A signed informed consent  
48 form will be obtained and preserved confidentially in the cabinet. The procedures of  
49 this clinical trial are shown in Figure 1.  
50  
51  
52  
53  
54  
55

### 56 **Groups, randomisation and blinding**

57  
58 An experienced endodontist will perform the examination, diagnosis and assessment  
59 procedures after clinical and radiographic examinations. The sequence and allocation  
60



1  
2  
3  
4 will be performed by a professor alone with opaque envelopes. The bone grafting  
5 material of the experimental group will be a PRF/ABBM composite, while the control  
6 group will receive ABBM only.  
7  
8

### 9 **Interventions**

10  
11 All enrolled patients will be randomly divided into two groups after examination. The  
12 endodontic microsurgery will be performed by the same experienced endodontist  
13 using an endodontic microscope (F40, Leica Microsystems Ltd, Wetzlar, Germany).  
14 The procedures and principles of the endodontic microsurgeries will follow the  
15 guidelines.<sup>29</sup> A vertical and a horizontal incision will be used to reflect the flap.  
16 Peri-radicular curettage will be performed after reaching the periapical lesion. After  
17 3mm of the root apex is resected, retro-preparation and retro-filling with iRoot BP  
18 (Innovative BioCeramix Inc., Burnaby, BC, Canada) will be performed. In the  
19 experimental group, after peri-radicular curettage, whole blood (10 mL) will be  
20 collected in sterile glass-coated centrifugal tube without any anticoagulant and  
21 centrifuged at 960 rpm (Medical centrifuge Auto V1, JM Instrument, Beijing, China)  
22 for 2.8 minutes. Then the buffy coat layer, the plasma layer, and 1 to 1.5 mm of the  
23 red blood cell layer below the buffy coat layer will be harvested as the liquid PRF.  
24 Finally, ABBM (Heal-all, ZH-Bio, Yantai, China) will be mixed with the liquid PRF  
25 evenly. ABBM is a category of xenograft which has only an osteoconductive effect.  
26 The periapical defects will be filled with PRF/ABBM complex in the experimental  
27 group while the periapical defects will be filled with ABBM only in the control group.  
28 An absorbable collagen membrane (Heal-all, ZH-Bio, Yantai, China) will be applied  
29 in both groups, then the flap will be repositioned with 6-0 sutures. Amoxicillin and  
30 0.2% chlorhexidine gluconate rinse will be prescribed to prevent postoperative  
31 infection. Sutures will be removed 5 days after the endodontic microsurgery.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 **Examination**

#### 53 **Baseline examination**

54 Before treatment, all participants will be examined carefully by a calibrated examiner.  
55  
56 Clinical examination including percussion and mobility testing and presence/absence  
57 of sinus will be recorded simultaneously. Preoperative paralleling radiographs and  
58  
59  
60

1  
2  
3  
4 CBCT scans will be obtained for each participant.

5  
6 Examination during the follow-up period

7  
8 Clinical examination including percussion, mobility testing and presence/absence of  
9  
10 sinus will be performed at 7 days, 3 months, 6 months and 12 months after the  
11  
12 endodontic microsurgery. In addition, a visual analogue scale (VAS) will be recorded  
13  
14 at 1 day, 3 days and 7 days after the endodontic microsurgery for the evaluation of  
15  
16 postoperative pain. Paralleling radiographs will be obtained at 3 months, 6 months  
17  
18 and 12 months. CBCT scans will be performed at the 12-month follow-up. The  
19  
20 grouping and the treatment plan will be confidential to the examiners. The primary  
21  
22 parameter of the present clinical trial is radiographic bone regeneration in the area of  
23  
24 the periapical defect. The paralleling radiographs and CBCT scans will be evaluated  
25  
26 both before and after microsurgery. Bone regeneration in periapical osseous defects  
27  
28 will be evaluated according to the radiopacity scoring scale of paralleling radiographs  
29  
30 by three independent blinded and calibrated examiners at the 3-month, 6-month and  
31  
32 12-month follow-ups after the microsurgery and compared with the paralleling  
33  
34 radiograph after microsurgery immediately. According to a previous study,<sup>30</sup> the  
35  
36 change in the volume of the periapical defect is the evaluation index of the radiopacity  
37  
38 scoring scale. CBCT data before and 12 months after microsurgery will be processed  
39  
40 using medical image processing software (MIMICS, Materialise, Leuven, Belgium) to  
41  
42 evaluate the changes of volume and density of the periapical defect. The data of the  
43  
44 clinical trial will be input and kept in a specific computer and a locked cabinet by two  
45  
46 designated member of staffs. The secondary parameters of this clinical trial include  
47  
48 percussion, mobility testing and presence/absence of sinus. The VAS scores are also  
49  
50 secondary parameters. All the data will be recorded and imputed in the computer  
51  
52 simultaneously. Due to lack of data monitoring committee in our hospital, the data  
53  
54 will be kept in the cabinet by two different researchers to make sure the accuracy and  
55  
56 completeness of the data. An independent inspector will review the incoming data  
57  
58 every 3 months. There will be no harms caused by the trial.

### 58 **Sample size**

59  
60 The sample size of this clinical trial is determined by the following formula:

$$N1 = N2 = 2 \left[ \frac{\sigma(Z_{\alpha/2} + Z_{\beta})}{\delta} \right]^2$$

According to the data of a published clinical trial, which is about bone grafting in periapical osseous defects,<sup>30</sup> the  $\sigma/\delta$  is around 0.49. The inspection level ( $\alpha$ ) is set to 0.05, and the power is set to 0.9. For bilateral tests, the required sample size in each group is six. Considering a missed follow-up rate of 20%, the sample size should be 7.2. Consequently 16 participants will be needed.

### **Statistical analysis**

Data will be analysed using SPSS software (SPSS, Inc, Chicago, IL, USA). Statistical significance will be accepted for  $P$  values lower than 0.05. Normality and variance equality will be analysed using the Shapiro-Wilk test and the Levene variance homogeneity test, respectively. Normally-distributed data will be shown as mean  $\pm$  standard deviation, while non-normally distributed data will be shown as median (lower to upper quartile). Student's  $t$ -test will be used to compare the difference between the two groups for the data with both normality and variance equality. Otherwise, the Mann-Whitney  $U$  test will be used.

### **Withdrawal**

The patients have the right to withdraw from this clinical trial without any reason at any point during the treatment. Follow-up treatment will not be affected by the withdrawal.

### **Dissemination of results**

The results of this clinical trial will be registered at the International Clinical Trials Registry Platform (ICTRP). In addition, the results will be published in a peer-reviewed journal.

### **Patient and Public Involvement**

Neither patients nor the public were involved in the design, recruitment, assessment, conduct and reporting of this research. The results will be disseminated through scientific journals.

## **DISCUSSION**

1  
2  
3  
4 When PRF is used together with ABBM, it increases the regenerative effect of  
5 osseous tissue, <sup>31, 32</sup> because ABBM only has an osteoconductive effect and  
6 osteoinduction is induced due to the growth factors in PRF. In a histological study,  
7 bone regenerative effects of PRF-TCP, rhBMP-2-coated TCP and TCP alone were  
8 compared, and the results showed that PRF-TCP resulted in more rapid bone healing  
9 compared to the other two groups. <sup>12</sup> The antibacterial and anti-inflammatory effects  
10 of PRF also promoted tissue healing. <sup>14</sup> Although PRF has many advantages,  
11 traditional PRF is not liquid, and it is challenging to mix PRF and ABBM evenly.  
12 Thus, in previous studies, <sup>33-35</sup> the gelatinous PRF had to be minced and then mixed  
13 with ABBM, which is time-consuming. Exposing alveolar bone to air could result in  
14 bone resorption, and a long duration of surgery is not favourable. <sup>36</sup> Therefore, our  
15 group developed a new technique to obtain a type of PRF/ABBM complex and thus  
16 avoid the need to mince the PRF. <sup>23, 24</sup> Additionally, PRF/ABBM complex as a whole  
17 had better applicability than granular ABBM, and could significantly reduce the time  
18 required for bone grafting. <sup>24</sup> The complex together with a collagen membrane has  
19 been demonstrated to result in enhanced gains in attachment level compared to  
20 ABBM alone with a collagen membrane, indicating improved periodontal  
21 regeneration. <sup>24</sup>

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39 To date there is still a lack of clinical trials investigating the osseous regenerative  
40 effect of PRF/bone grafting material composites in endodontic microsurgery. This  
41 randomised controlled trial is devoted to the evaluation of the clinical outcomes of the  
42 application of a PRF/ABBM complex as a grafting biomaterial in endodontic  
43 microsurgery cases with large lesion size, in the hope of providing some scientific  
44 evidence to support endodontic microsurgeries for dentists.

#### 45 46 47 48 49 50 **Ethics and dissemination**

51  
52 Ethical approval had been approved by the Ethics Committee of Peking University  
53 School and Hospital of Stomatology (PKUSSIRB-202059179). The data of the  
54 clinical trial will be input and kept in a specific computer and a locked cabinet by two  
55 designated member of staffs. The results will be published in a peer-reviewed journal.  
56  
57  
58  
59  
60 Research data will be registered with the International Clinical Trials Registry

Platform (ICTRP), ID: ChiCTR2100046684.

### **Trial status**

The trial has been registered at the International Clinical Trials Registry Platform (ICTRP). The identifier number is ChiCTR2100046684. Recruitment will begin in June 2021 and will end in June 2023.

### **Contributors**

The study concept was proposed by ZW, KL, ZC and BH. The manuscript was drafted by BH and KL. CZ and ZZ revised the part on randomisation. YW and YL calculated the sample size. ZW, XW and KL revised the manuscript finally. All authors have agreed with the final version of the manuscript.

### **Funding**

This work was supported by grants from the Program for New Clinical Techniques and Therapies of Peking University School and Hospital of Stomatology (PKUSSNCT-17B02 , PKUSSNCT-20A04 and PKUSSNCT-20B13).

### **Competing interests**

None declared.

### **Patient consent for publication**

Not required.

### **Provenance and peer review**

Not commissioned; externally peer-reviewed.

### **Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

### **References**

- 1 Monaghan L, Jadun S, Darcey J. Endodontic microsurgery. Part one: diagnosis, patient selection and prognoses. *Brit Dent J* 2019;226:940-8.
- 2 Rud J, Andreasen JO, Jensen JE. Radiographic criteria for the assessment of healing after endodontic surgery. *Int J Oral Surg* 1972;1:195-214.
- 3 Molven O, Halse A, Grung B. Observer strategy and the radiographic classification of healing after endodontic surgery. *Int J Oral Maxillofac Surg* 1987;16:432-9.
- 4 Wang ZH, Zhang MM, Wang J, *et al.* Outcomes of Endodontic Microsurgery Using a Microscope and Mineral Trioxide Aggregate: A Prospective Cohort Study. *J Endod* 2017;43:694-8.
- 5 Deng Y, Zhu X, Yang J, *et al.* The Effect of Regeneration Techniques on Periapical Surgery With Different Protocols for Different Lesion Types: A Meta-Analysis. *J Oral Maxillofac Surg* 2016;74:239-46.
- 6 Sánchez-Torres A, Sánchez-Garcés MÁ, Gay-Escoda C. Materials and prognostic factors of bone regeneration in periapical surgery: a systematic review. *Med Oral Patol Oral Cir Bucal* 2014;19: e419-25.
- 7 Tobón SI, Arismendi JA, Marín ML, *et al.* Comparison between a conventional technique and two bone regeneration techniques in periradicular surgery. *Int Endod J* 2002;35:635-41.
- 8 Chaturvedy V, Chaturvedy S. Regenerative therapy as an adjunct to periapical surgery: a case report. *Int J Clin Pediatr Dent* 2012;5:75-7.
- 9 Kim S, Kratchman S. *Microsurgery in Endodontics*. Wiley-Blackwell 2018.
- 10 Lin YC, Lee YY, Ho YC, *et al.* Treatment of large apical lesions with mucosal fenestration: a clinical study with long-term evaluation. *J Endod* 2015;41:563-7.
- 11 Chen FM, Liu X. Advancing biomaterials of human origin for tissue engineering. *Prog Polym Sci* 2016;53:86-168.
- 12 Kim BJ, Kwon TK, Baek HS, *et al.* A comparative study of the effectiveness of sinus bone grafting with recombinant human bone morphogenetic protein 2-coated tricalcium phosphate and platelet-rich fibrin-mixed tricalcium phosphate in rabbits. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2012;113:583-92.
- 13 Taschieri S, Rosano G, Weinstein T, *et al.* Treatment of through-and-through bone

1  
2  
3  
4 lesion using autologous growth factors and xenogeneic bone graft: a case report. *Oral*  
5 *Maxillofac Surg* 2012,16:57-64.

6  
7 14 Miron RJ, Zucchelli G, Pikos MA, *et al.* Use of platelet-rich fibrin in regenerative  
8 dentistry: a systematic review. *Clin Oral Investig* 2017,21:1913-27.

9  
10 15 Bielecki T, Dohan ED, Everts PA, *et al.* The role of leukocytes from  
11 L-PRP/L-PRF in wound healing and immune defense: new perspectives. *Curr Pharm*  
12 *Biotechnol* 2012,13:1153-62.

13  
14 16 Zhang J, Yin C, Zhao Q, *et al.* Anti-inflammation effects of injectable platelet-rich  
15 fibrin via macrophages and dendritic cells. *J Biomed Mater Res A* 2020,108:61-8.

16  
17 17 Jasmine S, Thangavelu A, Janarthanan K, *et al.* Antimicrobial and antibiofilm  
18 potential of injectable platelet rich fibrin-a second-generation platelet  
19 concentrate-against biofilm producing oral staphylococcus isolates. *Saudi J Biol Sci*  
20 2020,27:41-6.

21  
22 18 Daugela P, Grimuta V, Sakavicius D, *et al.* Influence of leukocyte- and  
23 platelet-rich fibrin (L-PRF) on the outcomes of impacted mandibular third molar  
24 removal surgery: A split-mouth randomized clinical trial. *Quintessence Int*  
25 2018,49:377-88.

26  
27 19 Temmerman A, Vandessel J, Castro A, *et al.* The use of leucocyte and platelet-rich  
28 fibrin in socket management and ridge preservation: a split-mouth, randomized,  
29 controlled clinical trial. *J Clin Periodontol* 2016,43:990-9.

30  
31 20 Pichotano EC, de Molon RS, de Souza RV, *et al.* Evaluation of L-PRF combined  
32 with deproteinized bovine bone mineral for early implant placement after maxillary  
33 sinus augmentation: A randomized clinical trial. *Clin Implant Dent Relat Res*  
34 2019,21:253-62.

35  
36 21 Bodhare GH, Kolte AP, Kolte RA, *et al.* Clinical and radiographic evaluation and  
37 comparison of bioactive bone alloplast morsels when used alone and in combination  
38 with platelet-rich fibrin in the treatment of periodontal intrabony defects-A  
39 randomized controlled trial. *J Periodontol* 2019,90:584-94.

40  
41 22 Pradeep AR, Bajaj P, Rao NS, *et al.* Platelet-Rich Fibrin Combined With a Porous  
42 Hydroxyapatite Graft for the Treatment of 3-Wall Intrabony Defects in Chronic  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Periodontitis: A Randomized Controlled Clinical Trial. *J Periodontol*  
5 2017,88:1288-96.

6  
7 23 Liu K, Huang Z, Chen Z, *et al.* Treating periodontal intrabony defects using guided  
8 tissue regeneration and Bio-Oss® with platelet-rich fibrin: study protocol for a  
9 self-controlled trial. *Clin Trials Orthop Disord* 2020,5:9-13.

10  
11 24 Liu K, Huang Z, Chen Z, *et al.* Treatment of periodontal intrabony defects using  
12 bovine porous bone mineral and guided tissue regeneration with/without platelet-rich  
13 fibrin: a randomized controlled clinical trial. *J Periodontol* 2021, Online ahead of  
14 print. Doi: 10.1002/JPER.20-0860.

15  
16 25 Varghese MP, Manuel S, Kumar LKS. Potential for Osseous Regeneration of  
17 Platelet-Rich Fibrin-A Comparative Study in Mandibular Third Molar Impaction  
18 Sockets. *J Oral Maxillofac Surg* 2017,75:1322-9.

19  
20 26 Bilginaylar K, Uyanik LO. Evaluation of the effects of platelet-rich fibrin and  
21 piezosurgery on outcomes after removal of impacted mandibular third molars. *Br J*  
22 *Oral Maxillofac Surg* 2016,54:629-33.

23  
24 27 Uppada UK, Kalakonda B, Koppolu P, *et al.* Combination of hydroxyapatite,  
25 platelet rich fibrin and amnion membrane as a novel therapeutic option in regenerative  
26 periapical endodontic surgery: Case series. *Int J Surg Case Rep* 2017,37:139-44.

27  
28 28 Hiremath H, Motiwala T, Jain P, *et al.* Use of second-generation platelet  
29 concentrate (platelet-rich fibrin) and hydroxyapatite in the management of large  
30 periapical inflammatory lesion: a computed tomography scan analysis. *Indian J Dent*  
31 *Res* 2014,25:517-20.

32  
33 29 Kim S, Kratchman S. Modern Endodontic Surgery Concepts and Practice: A  
34 Review. *J Endod* 2006,32:601-23.

35  
36 30 Nakkeeran KP, Saravanan K, Babu P, *et al.* Evaluation of bone regeneration in  
37 periapical osseous defects with and without platelet rich plasma, combined calcium  
38 sulfate and autologous bone graft - A comparative study. *J Stomatol Oral Maxillofac*  
39 *Surg* 2019,120:196-202.

40  
41 31 Kim NR, Lim BS, Park HC, *et al.* Effects of N-acetylcysteine on TEGDMA- and  
42 HEMA-induced suppression of osteogenic differentiation of human osteosarcoma  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 MG63 cells. *J Biomed Mater Res B Appl Biomater* 2011,98B:300-7.

5  
6 32 Jayalakshmi KB, Agarwal S, Singh MP, *et al.* Platelet-Rich Fibrin with  $\beta$   
7 -Tricalcium Phosphate-A Novel Approach for Bone Augmentation in Chronic  
8 Periapical Lesion: A Case Report. *Case Rep Dent* 2012,2012:902858.

9  
10  
11 33 Cortellini S, Castro AB, Temmerman A, *et al.* Leucocyte- and platelet-rich fibrin  
12 block for bone augmentation procedure: A proof-of-concept study. *J Clin Periodontol*  
13 2018,45:624-34.

14  
15  
16  
17 34 Lei L, Yu Y, Ke T, *et al.* The Application of Three-Dimensional Printing Model  
18 and Platelet-Rich Fibrin Technology in Guided Tissue Regeneration Surgery for  
19 Severe Bone Defects. *J Oral Implantol* 2019,45:35-43.

20  
21  
22  
23 35 Sezgin Y, Uraz A, Taner IL, *et al.* Effects of platelet-rich fibrin on healing of  
24 intra-bony defects treated with anorganic bovine bone mineral. *Braz Oral Res*  
25 2017,31:e15.

26  
27  
28  
29 36 Fickl S, Kerschull M, Schupbach P, *et al.* Bone loss after full-thickness and  
30 partial-thickness flap elevation. *J Clin Periodontol* 2011,38:157-62.

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48 **Figure Legend:**

49 **Figure 1** The flow chart of this clinical research  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 The flow chart of this clinical research

189x175mm (600 x 600 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	11
Funding	4	Sources and types of financial, material, and other Support	12
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 2, 11
	5b	Name and contact information for the trial sponsor	12
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for Undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5, 6
	6b	Explanation for choice of comparators	6
Objectives	7	Specific objectives or hypotheses	6

1				
2	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
3				
4				
5				
6				
7				
8	<b>Methods: Participants, interventions, and outcomes</b>			
9				
10	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6, 7
11				
12				
13				
14	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
15				
16				
17				
18				
19	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8
20				
21				
22		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
23				
24				
25				
26				
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	N/A
29				
30				
31				
32		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
33				
34				
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8, 9
36				
37				
38				
39				
40				
41				
42				
43				
44				
45	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7, 8, 9
46				
47				
48				
49	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	9, 10
50				
51				
52				
53				
54	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7
55				
56				

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

1				
2	Sequence	16a	Method of generating the allocation sequence	7, 8
3	generation		(eg, computer-generated random numbers), and list of	
4			any factors for stratification. To reduce predictability of a	
5			random sequence, details of any planned restriction (eg, blocking)	
6			should be provided in a separate document that is unavailable to	
7			those who enrol participants or assign interventions	
8				
9				
10	Allocation	16b	Mechanism of implementing the allocation sequence	7, 8
11	concealment		(eg, central telephone; sequentially numbered, opaque, sealed	
12	mechanism		envelopes), describing any steps to conceal the sequence until	
13			interventions are assigned	
14				
15	Implementation	16c	Who will generate the allocation sequence,	7, 8
16			who will enrol participants, and who will assign participants to	
17			interventions	
18				
19				
20	Blinding	17a	Who will be blinded after assignment to interventions	8, 9
21	(masking)		(eg, trial participants, care providers, outcome assessors,	
22			data analysts), and how	
23				
24				
25		17b	If blinded, circumstances under which unblinding	N/A
26			is permissible, and procedure for revealing a participant's	
27			allocated intervention during the trial	
28				
29	<b>Methods: Data collection, management, and analysis</b>			
30				
31	Data collection	18a	Plans for assessment and collection of outcome, baseline	8, 9
32	methods		and other trial data, including any related processes to	
33			promote data quality (eg, duplicate measurements, training of	
34			assessors) and a description of study instruments	
35			(eg, questionnaires, laboratory tests) along with their	
36			reliability and validity, if known. Reference to where data	
37			collection forms can be found, if not in the protocol	
38				
39				
40				
41		18b	Plans to promote participant retention and complete	9, 10
42			follow-up, including list of any outcome data to be collected	
43			for participants who discontinue or deviate from intervention protocols	
44				
45	Data	19	Plans for data entry, coding, security, and storage,	9
46	management		including any related processes to promote data quality	
47			(eg, double data entry; range checks for data values). Reference to	
48			where details of data management procedures can be found, if not in	
49			the protocol	
50				
51				
52	Statistical	20a	Statistical methods for analysing primary and secondary	10
53	methods		outcomes. Reference to where other details of the statistical	
54			analysis plan can be found, if not in the protocol	
55				
56		20b	Methods for any additional analyses (eg, subgroup and	N/A
57			adjusted analyses)	
58				
59				
60				

1				
2		20c	Definition of analysis population relating to protocol	N/A
3			non-adherence (eg, as randomised analysis), and any	
4			statistical methods to handle missing data (eg, multiple imputation)	
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

### Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	9
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	9
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	9

### Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	11
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	N/A
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	11
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	12
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	11

1				
2	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for	N/A
3	post-trial care		compensation to those who suffer harm from trial participation	
4				
5	Dissemination	31a	Plans for investigators and sponsor to communicate trial	11
6	policy		results to participants, healthcare professionals, the public,	
7			and other relevant groups (eg, via publication, reporting in	
8			results databases, or other data sharing arrangements),	
9			including any publication restrictions	
10				
11		31b	Authorship eligibility guidelines and any intended use of	N/A
12			professional writers	
13				
14		31c	Plans, if any, for granting public access to the full protocol,	N/A
15			participant-level dataset, and statistical code	
16				
17				
18				
19	<b>Appendices</b>			
20				
21	Informed consent	32	Model consent form and other related documentation	Additional file
22	materials		given to participants and authorised surrogates	
23				
24	Biological	33	Plans for collection, laboratory evaluation, and storage	N/A
25	specimens		Of biological specimens for genetic or molecular analysis in the	
26			current trial and for future use in ancillary studies, if applicable	
27				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Platelet-rich fibrin/anorganic bovine bone mineral complex as grafting materials in endodontic microsurgery with a large lesion size: study protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057068.R2
Article Type:	Protocol
Date Submitted by the Author:	08-Mar-2022
Complete List of Authors:	Han, Bing; Peking University School of Stomatology, Department of Cariology and Endodontology Wang, Yuhan; Peking University School of Stomatology, Department of Cariology and Endodontology Chen, Zhibin; Peking University School of Stomatology, Department of Periodontology Zheng, Chunyan; Peking University School of Stomatology, Department of Cariology and Endodontology Zhang, Zhichun; Peking University School of Stomatology, Department of Cariology and Endodontology Liu, Yingyi; Peking University School of Stomatology, Department of Cariology and Endodontology Liu, Kaining; Peking University School of Stomatology, Department of Periodontology Wang, Zuhua; Peking University School of Stomatology, Department of Cariology and Endodontology Wang, Xiaoyan; Peking University School of Stomatology, Department of Cariology and Endodontology
<b>Primary Subject Heading</b>:	Dentistry and oral medicine
Secondary Subject Heading:	Dentistry and oral medicine
Keywords:	Clinical trials < THERAPEUTICS, ORAL MEDICINE, ORAL & MAXILLOFACIAL SURGERY

SCHOLARONE™  
Manuscripts



1  
2  
3  
4 **Platelet-rich fibrin/anorganic bovine bone mineral complex as grafting materials**  
5 **in endodontic microsurgery with a large lesion size: study protocol for a**  
6 **randomised controlled trial**  
7  
8  
9

10  
11 Bing Han<sup>1</sup>, Yuhan Wang<sup>1</sup>, Zhibin Chen<sup>2,\*</sup>, Chunyan Zheng<sup>1</sup>, ZhiChun Zhang<sup>1</sup>,  
12 YingYi Liu<sup>1</sup>, Kaining Liu<sup>2,\*</sup>, Zuhua Wang<sup>1,\*</sup>, Xiaoyan Wang<sup>1</sup>  
13  
14  
15

16  
17 1 Department of Cariology and Endodontology, Peking University School and  
18 Hospital of Stomatology & National Clinical Research Center for Oral Diseases &  
19 National Engineering Laboratory for Digital and Material Technology of Stomatology  
20 & Beijing Key Laboratory of Digital Stomatology, Beijing, China  
21  
22

23  
24 2 Department of Periodontology, Peking University School and Hospital of  
25 Stomatology & National Clinical Research Center for Oral Diseases & National  
26 Engineering Laboratory for Digital and Material Technology of Stomatology &  
27 Beijing Key Laboratory of Digital Stomatology, Beijing, China  
28  
29  
30  
31  
32

33  
34  
35 **\* Corresponding author**

36 Dr. Zhibin Chen

37  
38 Mail address: Department of Periodontology, Peking University School and Hospital  
39 of Stomatology, 22 Zhongguancun South Street, Haidian District, Beijing, 100081,  
40  
41 China  
42  
43

44 Fax number: 86-10-62173402

45  
46 E-mail: czb0774@sina.com  
47  
48  
49

50 Dr. Kaining Liu

51  
52 Mail address: Department of Periodontology, Peking University School and Hospital  
53 of Stomatology, 22 Zhongguancun South Street, Haidian District, Beijing, 100081,  
54  
55 China  
56  
57

58 Fax number: 86-10-62173402

59  
60 E-mail: liukainingbjmu@163.com

1  
2  
3  
4 Dr. Zuhua Wang

5 Mailing address: Department of Cariology and Endodontology, Peking University  
6 School and Hospital of Stomatology, 22 Zhongguancun South Street, Haidian District,  
7 Beijing, 100081, China  
8

9  
10  
11 Fax number: 86-10-62173402

12  
13 E-mail: wangzuhua@pkuss.bjmu.edu.cn  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ABSTRACT

**Introduction:** Endodontic microsurgery is a treatment of last resort for preserving natural teeth. According to radiographic evaluation, the percentage of complete healing after endodontic microsurgery is only 74.3%. The use of regenerative techniques in endodontic microsurgery for large lesions (>10 mm diameter) is therefore recommended. The most frequently used bone graft in endodontic microsurgery is anorganic bovine bone mineral (ABBM) but this only has an osteoconductive effect. Thus, when platelet-rich fibrin (PRF), a reservoir of growth factors, is used together with ABBM, it increases the regenerative effect. This study is devoted to comparing the clinical outcomes of PRF with/without ABBM as grafting biomaterials in endodontic microsurgery cases with large lesion size to provide some valuable reference data for dentists.

**Methods and analysis:** Sixteen patients who are in need of endodontic microsurgery will be recruited. The patients will be randomly assigned to one of two groups: an experimental group, treated with PRF/ABBM complex and collagen membrane, and a control group, treated with ABBM and collagen membrane. Clinical examination including percussion, mobility testing and presence/absence of sinus will be recorded at 7 days, and at 3, 6 and 12 months after endodontic microsurgery. A visual analogue scale (VAS) will be used by the patients to evaluate pain at 1, 3 and 7 days after endodontic microsurgery. Routine paralleling radiographs will be obtained before and at 3, 6 and 12 months follow-up after endodontic microsurgery. Cone-beam computed tomographic (CBCT) scans will be obtained at the 12-month follow-up. Bone formation will be evaluated according to CBCT and paralleling radiographs. The study execute time including follow-ups last from June 1<sup>st</sup> 2021 to December 31<sup>st</sup> 2024.

**Ethics and dissemination:** The present study received approval from the Ethics Committee of Peking University School and Hospital of Stomatology. Research data will be registered with the International Clinical Trials Registry Platform (ICTRP), ID: ChiCTR2100046684. The results will be disseminated through scientific journals.

**Strengths and limitations of this study:**

1  
2  
3  
4 This trial is designed as a randomised, double-blind clinical trial.

5  
6 The trial will be the first clinical trial with a novel design to compare the clinical and  
7  
8 radiographic effects of PRF/ABBM complex and ABBM on large periapical lesions  
9  
10 (>10 mm diameter) after endodontic microsurgery.

11  
12 This study will collect longitudinal data on patients during the subsequent 12-month  
13  
14 follow-up.

15  
16 The patients with systemic disease will not be included in this research.

17  
18 **Keywords:** Platelet-rich fibrin, Endodontic microsurgery, Large lesion size,  
19  
20 Osteoinduction, Regeneration techniques  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

With developments in equipment, instruments and biomaterials, endodontic microsurgery has become available as a treatment of last resort for cases which are no longer suitable for retreatment.<sup>1</sup> It is generally accepted that radiographic outcomes can be classified into complete healing, incomplete healing, uncertain healing and unsatisfactory healing.<sup>2,3</sup> Complete bone repair is the ideal therapeutic outcome of endodontic microsurgery, however, the percentage of complete radiographic healing after endodontic microsurgery is only 74.3%.<sup>4</sup> Thus, it is imperative to promote healing of periapical bone defects more effectively. The results of endodontic microsurgery can be influenced by several factors, especially lesion size<sup>5,6</sup>. During the healing process, epithelial cells repopulate the wound at the highest rate which results in scar formation.<sup>7</sup> Once complete osseous regeneration of a defect cannot occur, the defect will be filled by fibrous connective tissue.<sup>8</sup> It has been demonstrated that 26% of defects radiographically larger than 10 mm result in scar formation after endodontic microsurgery.<sup>9</sup> Thus, usage of grafting materials and membrane in cases with large lesion size (>10mm diameter) is recommended.<sup>5,6,10</sup>

There are four types of bone grafts: autogenous grafts, allogeneic grafts, xenogeneic grafts and alloplastic materials. Autogenous grafts and allogeneic grafts are osteoinductive materials, while xenogeneic grafts and alloplastic materials are osteoconductive materials due to their lack of growth factors.<sup>11</sup> It has been reported that a combination of osteoconductive materials (e.g. anorganic bovine bone mineral (ABBM)) and growth factors results in faster and better healing of bone in endodontic microsurgery than osteoconductive materials only.<sup>12,13</sup>

PRF (platelet-rich fibrin) contains platelets, leukocytes and more than 100 types of growth factors including platelet-derived growth factor (PDGF), transforming growth factor-beta 1 (TGF- $\beta$ 1), vascular endothelial growth factor (VEGF) and bone morphogenetic protein 2 (BMP-2), which promote the proliferation and differentiation of osteoblasts.<sup>14</sup> Moreover, the presence of leukocytes is helpful for their anti-infection and immunomodulatory effects.<sup>15-17</sup> Previously, PRF has been extensively used in dentistry, including the healing of extraction sockets,<sup>18</sup> ridge

1  
2  
3  
4 preservation, <sup>19</sup> maxillary sinus augmentation and the regeneration of periodontal  
5 lesions. <sup>20-24</sup> It promotes the healing of soft tissue, and reduces postoperative pain,  
6 swelling, and the incidence of alveolar osteitis after the extraction of impacted  
7 mandibular third molars. <sup>18</sup> Compared with natural healing, horizontal and vertical  
8 dimension ridge preservation is more effective with the use of PRF. <sup>19</sup> The  
9 combination of PRF and deproteinized bovine bone mineral has been shown to  
10 increase bone formation in maxillary sinus augmentation compared with  
11 deproteinized bovine bone mineral alone. <sup>20</sup> Plenty of studies have indicated that  
12 combinations of PRF and bone grafting materials enhance periodontal regeneration in  
13 periodontal intrabony defects. <sup>21-24</sup> In a word, PRF has the potential for osseous  
14 regeneration and healing of soft tissue, especially when combined with various bone  
15 grafting materials. <sup>25</sup> It was also indicated that PRF reduces post-operative pain and  
16 infections due to the improvements in soft-tissue healing and the presence of  
17 microbial-fighting immune cells. <sup>26</sup> Hitherto, there have only been two case reports in  
18 which PRF was used together with osteoconductive bone grafts in periapical surgery  
19 in order to achieve a better healing outcome. <sup>27, 28</sup> With the exception of these two  
20 case reports, there has been no clinical research into the effects of PRF in periapical  
21 surgery.

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39 We hypothesized that PRF combined with ABBM and collagen membrane is  
40 more effective than using only ABBM and collagen membrane in endodontic  
41 microsurgery. The hypothesis will be tested in the present double-masked randomised  
42 controlled clinical trial, the design of which is described below.

## 43 44 45 46 47 48 49 **METHODS AND ANALYSIS**

50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The study is a prospective, single-centre randomised controlled trial. It had been approved by the Ethics Committee of Peking University School and Hospital of Stomatology (PKUSSIRB-202059179). Research procedures including assessments, interventions and follow-ups will be carried out in Peking University School and Hospital of Stomatology (Beijing, China). This study has been registered with the registry of ICTRP (ID: ChiCTR2100046684). The main objective of this randomised

1  
2  
3  
4 controlled clinical trial is to compare and evaluate the clinical effects of PRF with or  
5 without combination with ABBM in endodontic microsurgery cases with large lesion  
6 size (>10 mm diameter). The primary hypothesis is that healing of periapical lesions  
7 will be better in the PRF/ABBM complex group.  
8  
9  
10

### 11 12 13 **Inclusion criteria**

14  
15 Patients attending the Department of Cariology and Endodontology for routine  
16 planned endodontic microsurgery will be evaluated for inclusion in this clinical trial.  
17 The age of patients to be recruited will range from 18 to 65 years. Patients will have  
18 received periodontal treatment before endodontic microsurgery. Only single-rooted  
19 teeth will be included in the study, and the periapical lesions should be classified as  
20 large periapical lesions (>10mm diameter) according to cone-beam computed  
21 tomographic (CBCT) evaluation.  
22  
23  
24  
25  
26  
27  
28

### 29 **Exclusion criteria**

- 30 1. Smokers;
  - 31 2. Pregnant women;
  - 32 3. Patients with systemic diseases;
  - 33 4. Re-surgery;
  - 34 5. Unqualified coronal restoration;
  - 35 6. Teeth with deep periodontal pockets (probing depth  $\geq 5$ mm).
- 36  
37  
38  
39  
40  
41  
42

### 43 **Recruitment**

44 Patients who are willing to participate in this study will be recruited from the  
45 Department of Cariology and Endodontology, Peking University School and Hospital  
46 of Stomatology. The necessity of endodontic microsurgery and collecting blood for  
47 PRF/ABBM complex will be explained to the participants. A signed informed consent  
48 form will be obtained and preserved confidentially in the cabinet. The procedures of  
49 this clinical trial are shown in Figure 1.  
50  
51  
52  
53  
54  
55

### 56 **Groups, randomisation and blinding**

57 An experienced endodontist will perform the examination, diagnosis and assessment  
58 procedures after clinical and radiographic examinations. The sequence and allocation  
59  
60

1  
2  
3  
4 will be performed by a professor alone with opaque envelopes. The bone grafting  
5 material of the experimental group will be a PRF/ABBM composite, while the control  
6 group will receive ABBM only.  
7  
8

### 9 **Interventions**

10  
11 All enrolled patients will be randomly divided into two groups after examination. The  
12 endodontic microsurgery will be performed by the same experienced endodontist  
13 using an endodontic microscope (F40, Leica Microsystems Ltd, Wetzlar, Germany).  
14 The procedures and principles of the endodontic microsurgeries will follow the  
15 guidelines.<sup>29</sup> A vertical and a horizontal incision will be used to reflect the flap.  
16 Peri-radicular curettage will be performed after reaching the periapical lesion. After  
17 3mm of the root apex is resected, retro-preparation and retro-filling with iRoot BP  
18 (Innovative BioCeramix Inc., Burnaby, BC, Canada) will be performed. In the  
19 experimental group, after peri-radicular curettage, whole blood (10 mL) will be  
20 collected in sterile glass-coated centrifugal tube without any anticoagulant and  
21 centrifuged at 960 rpm (Medical centrifuge Auto V1, JM Instrument, Beijing, China)  
22 for 2.8 minutes. Then the buffy coat layer, the plasma layer, and 1 to 1.5 mm of the  
23 red blood cell layer below the buffy coat layer will be harvested as the liquid PRF.  
24 Finally, ABBM (Heal-all, ZH-Bio, Yantai, China) will be mixed with the liquid PRF  
25 evenly. ABBM is a category of xenograft which has only an osteoconductive effect.  
26 The periapical defects will be filled with PRF/ABBM complex in the experimental  
27 group while the periapical defects will be filled with ABBM only in the control group.  
28 An absorbable collagen membrane (Heal-all, ZH-Bio, Yantai, China) will be applied  
29 in both groups, then the flap will be repositioned with 6-0 sutures. Amoxicillin and  
30 0.2% chlorhexidine gluconate rinse will be prescribed to prevent postoperative  
31 infection. Sutures will be removed 5 days after the endodontic microsurgery.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 **Examination**

#### 53 **Baseline examination**

54 Before treatment, all participants will be examined carefully by a calibrated examiner.  
55  
56 Clinical examination including percussion and mobility testing and presence/absence  
57 of sinus will be recorded simultaneously. Preoperative paralleling radiographs and  
58  
59  
60



1  
2  
3  
4 CBCT scans will be obtained for each participant.

5  
6 Examination during the follow-up period

7  
8 Clinical examination including percussion, mobility testing and presence/absence of  
9  
10 sinus will be performed at 7 days, 3 months, 6 months and 12 months after the  
11  
12 endodontic microsurgery. In addition, a visual analogue scale (VAS) will be recorded  
13  
14 at 1 day, 3 days and 7 days after the endodontic microsurgery for the evaluation of  
15  
16 postoperative pain. Paralleling radiographs will be obtained at 3 months, 6 months  
17  
18 and 12 months. CBCT scans will be performed at the 12-month follow-up. The  
19  
20 grouping and the treatment plan will be confidential to the examiners. The primary  
21  
22 parameter of the present clinical trial is radiographic bone regeneration in the area of  
23  
24 the periapical defect. The paralleling radiographs and CBCT scans will be evaluated  
25  
26 both before and after microsurgery. Bone regeneration in periapical osseous defects  
27  
28 will be evaluated according to the radiopacity scoring scale of paralleling radiographs  
29  
30 by three independent blinded and calibrated examiners at the 3-month, 6-month and  
31  
32 12-month follow-ups after the microsurgery and compared with the paralleling  
33  
34 radiograph after microsurgery immediately. According to a previous study,<sup>30</sup> the  
35  
36 change in the volume of the periapical defect is the evaluation index of the radiopacity  
37  
38 scoring scale. CBCT data before and 12 months after microsurgery will be processed  
39  
40 using medical image processing software (MIMICS, Materialise, Leuven, Belgium) to  
41  
42 evaluate the changes of volume and density of the periapical defect. The data of the  
43  
44 clinical trial will be input and kept in a specific computer and a locked cabinet by two  
45  
46 designated member of staffs. The secondary parameters of this clinical trial include  
47  
48 percussion, mobility testing and presence/absence of sinus. The VAS scores are also  
49  
50 secondary parameters. All the data will be recorded and imputed in the computer  
51  
52 simultaneously. Due to lack of data monitoring committee in our hospital, the data  
53  
54 will be kept in the cabinet by two different researchers to make sure the accuracy and  
55  
56 completeness of the data. An independent inspector will review the incoming data  
57  
58 every 3 months. There will be no harms caused by the trial.

### 58 **Sample size**

59  
60 The sample size of this clinical trial is determined by the following formula:

$$N1 = N2 = 2 \left[ \frac{\sigma(Z_{\alpha/2} + Z_{\beta})}{\delta} \right]^2$$

According to the data of a published clinical trial, which is about bone grafting in periapical osseous defects,<sup>30</sup> the  $\sigma/\delta$  is around 0.49. The inspection level ( $\alpha$ ) is set to 0.05, and the power is set to 0.9. For bilateral tests, the required sample size in each group is six. Considering a missed follow-up rate of 20%, the sample size should be 7.2. Consequently 16 participants will be needed. Once more than 20% participants withdrawal occur, new participants will be enrolled.

### **Statistical analysis**

Data will be analysed using SPSS software (SPSS, Inc, Chicago, IL, USA). Statistical significance will be accepted for  $P$  values lower than 0.05. Normality and variance equality will be analysed using the Shapiro-Wilk test and the Levene variance homogeneity test, respectively. Normally-distributed data will be shown as mean  $\pm$  standard deviation, while non-normally distributed data will be shown as median (lower to upper quartile). Student's  $t$ -test will be used to compare the difference between the two groups for the data with both normality and variance equality. Otherwise, the Mann-Whitney  $U$  test will be used.

### **Withdrawal**

The patients have the right to withdraw from this clinical trial without any reason at any point during the treatment. Follow-up treatment will not be affected by the withdrawal.

### **Dissemination of results**

The results of this clinical trial will be registered at the International Clinical Trials Registry Platform (ICTRP). In addition, the results will be published in a peer-reviewed journal.

### **Patient and Public Involvement**

Neither patients nor the public were involved in the design, recruitment, assessment, conduct and reporting of this research. The results will be disseminated through scientific journals.

## DISCUSSION

When PRF is used together with ABBM, it increases the regenerative effect of osseous tissue,<sup>31, 32</sup> because ABBM only has an osteoconductive effect and osteoinduction is induced due to the growth factors in PRF. In a histological study, bone regenerative effects of PRF-TCP, rhBMP-2-coated TCP and TCP alone were compared, and the results showed that PRF-TCP resulted in more rapid bone healing compared to the other two groups.<sup>12</sup> The antibacterial and anti-inflammatory effects of PRF also promoted tissue healing.<sup>14</sup> Although PRF has many advantages, traditional PRF is not liquid, and it is challenging to mix PRF and ABBM evenly. Thus, in previous studies,<sup>33-35</sup> the gelatinous PRF had to be minced and then mixed with ABBM, which is time-consuming. Exposing alveolar bone to air could result in bone resorption, and a long duration of surgery is not favourable.<sup>36</sup> Therefore, our group developed a new technique to obtain a type of PRF/ABBM complex and thus avoid the need to mince the PRF.<sup>23, 24</sup> Additionally, PRF/ABBM complex as a whole had better applicability than granular ABBM, and could significantly reduce the time required for bone grafting.<sup>24</sup> The complex together with a collagen membrane has been demonstrated to result in enhanced gains in attachment level compared to ABBM alone with a collagen membrane, indicating improved periodontal regeneration.<sup>24</sup>

To date there is still a lack of clinical trials investigating the osseous regenerative effect of PRF/bone grafting material composites in endodontic microsurgery. This randomised controlled trial is devoted to the evaluation of the clinical outcomes of the application of a PRF/ABBM complex as a grafting biomaterial in endodontic microsurgery cases with large lesion size, in the hope of providing some scientific evidence to support endodontic microsurgeries for dentists.

### **Ethics and dissemination**

Ethical approval had been approved by the Ethics Committee of Peking University School and Hospital of Stomatology (PKUSSIRB-202059179). The data of the clinical trial will be input and kept in a specific computer and a locked cabinet by two designated member of staffs. The results will be published in a peer-reviewed journal.

1  
2  
3  
4 Research data will be registered with the International Clinical Trials Registry  
5 Platform (ICTRP), ID: ChiCTR2100046684.  
6

### 7 **Trial status**

8  
9 The trial has been registered at the International Clinical Trials Registry Platform  
10 (ICTRP). The identifier number is ChiCTR2100046684. Recruitment will begin in  
11 June 2021 and will end in June 2023.  
12  
13

### 14 **Contributors**

15  
16 The study concept was proposed by ZW, KL, ZC and BH. The manuscript was  
17 drafted by BH and KL. CZ and ZZ revised the part on randomisation. YW and YL  
18 calculated the sample size. ZW, XW and KL revised the manuscript finally. All  
19 authors have agreed with the final version of the manuscript.  
20  
21  
22  
23

### 24 **Funding**

25  
26 This work was supported by grants from the Program for New Clinical Techniques  
27 and Therapies of Peking University School and Hospital of Stomatology  
28 (PKUSSNCT-17B02 , PKUSSNCT-20A04 and PKUSSNCT-20B13).  
29  
30  
31  
32

### 33 **Competing interests**

34  
35 None declared.  
36

### 37 **Patient consent for publication**

38  
39 Not required.  
40

### 41 **Provenance and peer review**

42  
43 Not commissioned; externally peer-reviewed.  
44

### 45 **Open access**

46  
47 This is an open access article distributed in accordance with the Creative Commons  
48 Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to  
49 distribute, remix, adapt, build upon this work non-commercially, and license their  
50 derivative works on different terms, provided the original work is properly cited,  
51 appropriate credit is given, any changes made indicated, and the use is  
52 non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.  
53  
54  
55  
56  
57  
58  
59  
60

## References

- 1 Monaghan L, Jadun S, Darcey J. Endodontic microsurgery. Part one: diagnosis, patient selection and prognoses. *Brit Dent J* 2019;226:940-8.
- 2 Rud J, Andreasen JO, Jensen JE. Radiographic criteria for the assessment of healing after endodontic surgery. *Int J Oral Surg* 1972;1:195-214.
- 3 Molven O, Halse A, Grung B. Observer strategy and the radiographic classification of healing after endodontic surgery. *Int J Oral Maxillofac Surg* 1987;16:432-9.
- 4 Wang ZH, Zhang MM, Wang J, *et al.* Outcomes of Endodontic Microsurgery Using a Microscope and Mineral Trioxide Aggregate: A Prospective Cohort Study. *J Endod* 2017;43:694-8.
- 5 Deng Y, Zhu X, Yang J, *et al.* The Effect of Regeneration Techniques on Periapical Surgery With Different Protocols for Different Lesion Types: A Meta-Analysis. *J Oral Maxillofac Surg* 2016;74:239-46.
- 6 Sánchez-Torres A, Sánchez-Garcés MÁ, Gay-Escoda C. Materials and prognostic factors of bone regeneration in periapical surgery: a systematic review. *Med Oral Patol Oral Cir Bucal* 2014;19: e419-25.
- 7 Tobón SI, Arismendi JA, Marín ML, *et al.* Comparison between a conventional technique and two bone regeneration techniques in periradicular surgery. *Int Endod J* 2002;35:635-41.
- 8 Chaturvedy V, Chaturvedy S. Regenerative therapy as an adjunct to periapical surgery: a case report. *Int J Clin Pediatr Dent* 2012;5:75-7.
- 9 Kim S, Kratchman S. *Microsurgery in Endodontics*. Wiley-Blackwell 2018.
- 10 Lin YC, Lee YY, Ho YC, *et al.* Treatment of large apical lesions with mucosal fenestration: a clinical study with long-term evaluation. *J Endod* 2015;41:563-7.
- 11 Chen FM, Liu X. Advancing biomaterials of human origin for tissue engineering. *Prog Polym Sci* 2016;53:86-168.
- 12 Kim BJ, Kwon TK, Baek HS, *et al.* A comparative study of the effectiveness of sinus bone grafting with recombinant human bone morphogenetic protein 2-coated tricalcium phosphate and platelet-rich fibrin-mixed tricalcium phosphate in rabbits. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2012;113:583-92.

1  
2  
3  
4 13 Taschieri S, Rosano G, Weinstein T, *et al.* Treatment of through-and-through bone  
5 lesion using autologous growth factors and xenogeneic bone graft: a case report. *Oral*  
6 *Maxillofac Surg* 2012,16:57-64.  
7

8  
9 14 Miron RJ, Zucchelli G, Pikos MA, *et al.* Use of platelet-rich fibrin in regenerative  
10 dentistry: a systematic review. *Clin Oral Investig* 2017,21:1913-27.  
11

12  
13 15 Bielecki T, Dohan ED, Everts PA, *et al.* The role of leukocytes from  
14 L-PRP/L-PRF in wound healing and immune defense: new perspectives. *Curr Pharm*  
15 *Biotechnol* 2012,13:1153-62.  
16

17  
18 16 Zhang J, Yin C, Zhao Q, *et al.* Anti-inflammation effects of injectable platelet-rich  
19 fibrin via macrophages and dendritic cells. *J Biomed Mater Res A* 2020,108:61-8.  
20

21  
22 17 Jasmine S, Thangavelu A, Janarthanan K, *et al.* Antimicrobial and antibiofilm  
23 potential of injectable platelet rich fibrin-a second-generation platelet  
24 concentrate-against biofilm producing oral staphylococcus isolates. *Saudi J Biol Sci*  
25 2020,27:41-6.  
26

27  
28 18 Daugela P, Grimuta V, Sakavicius D, *et al.* Influence of leukocyte- and  
29 platelet-rich fibrin (L-PRF) on the outcomes of impacted mandibular third molar  
30 removal surgery: A split-mouth randomized clinical trial. *Quintessence Int*  
31 2018,49:377-88.  
32

33  
34 19 Temmerman A, Vandessel J, Castro A, *et al.* The use of leucocyte and platelet-rich  
35 fibrin in socket management and ridge preservation: a split-mouth, randomized,  
36 controlled clinical trial. *J Clin Periodontol* 2016,43:990-9.  
37

38  
39 20 Pichotano EC, de Molon RS, de Souza RV, *et al.* Evaluation of L-PRF combined  
40 with deproteinized bovine bone mineral for early implant placement after maxillary  
41 sinus augmentation: A randomized clinical trial. *Clin Implant Dent Relat Res*  
42 2019,21:253-62.  
43

44  
45 21 Bodhare GH, Kolte AP, Kolte RA, *et al.* Clinical and radiographic evaluation and  
46 comparison of bioactive bone alloplast morsels when used alone and in combination  
47 with platelet-rich fibrin in the treatment of periodontal intrabony defects-A  
48 randomized controlled trial. *J Periodontol* 2019,90:584-94.  
49

50  
51 22 Pradeep AR, Bajaj P, Rao NS, *et al.* Platelet-Rich Fibrin Combined With a Porous  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Hydroxyapatite Graft for the Treatment of 3-Wall Intrabony Defects in Chronic  
5 Periodontitis: A Randomized Controlled Clinical Trial. *J Periodontol*  
6 2017,88:1288-96.  
7

8  
9 23 Liu K, Huang Z, Chen Z, *et al.* Treating periodontal intrabony defects using guided  
10 tissue regeneration and Bio-Oss® with platelet-rich fibrin: study protocol for a  
11 self-controlled trial. *Clin Trials Orthop Disord* 2020,5:9-13.  
12

13  
14 24 Liu K, Huang Z, Chen Z, *et al.* Treatment of periodontal intrabony defects using  
15 bovine porous bone mineral and guided tissue regeneration with/without platelet-rich  
16 fibrin: a randomized controlled clinical trial. *J Periodontol* 2021, Online ahead of  
17 print. Doi: 10.1002/JPER.20-0860.  
18

19  
20 25 Varghese MP, Manuel S, Kumar LKS. Potential for Osseous Regeneration of  
21 Platelet-Rich Fibrin-A Comparative Study in Mandibular Third Molar Impaction  
22 Sockets. *J Oral Maxillofac Surg* 2017,75:1322-9.  
23

24  
25 26 Bilginaylar K, Uyanik LO. Evaluation of the effects of platelet-rich fibrin and  
26 piezosurgery on outcomes after removal of impacted mandibular third molars. *Br J*  
27 *Oral Maxillofac Surg* 2016,54:629-33.  
28

29  
30 27 Uppada UK, Kalakonda B, Koppolu P, *et al.* Combination of hydroxyapatite,  
31 platelet rich fibrin and amnion membrane as a novel therapeutic option in regenerative  
32 periapical endodontic surgery: Case series. *Int J Surg Case Rep* 2017,37:139-44.  
33

34  
35 28 Hiremath H, Motiwala T, Jain P, *et al.* Use of second-generation platelet  
36 concentrate (platelet-rich fibrin) and hydroxyapatite in the management of large  
37 periapical inflammatory lesion: a computed tomography scan analysis. *Indian J Dent*  
38 *Res* 2014,25:517-20.  
39

40  
41 29 Kim S, Kratchman S. Modern Endodontic Surgery Concepts and Practice: A  
42 Review. *J Endod* 2006,32:601-23.  
43

44  
45 30 Nakkeeran KP, Saravanan K, Babu P, *et al.* Evaluation of bone regeneration in  
46 periapical osseous defects with and without platelet rich plasma, combined calcium  
47 sulfate and autologous bone graft - A comparative study. *J Stomatol Oral Maxillofac*  
48 *Surg* 2019,120:196-202.  
49

50  
51 31 Kim NR, Lim BS, Park HC, *et al.* Effects of N-acetylcysteine on TEGDMA- and  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 HEMA-induced suppression of osteogenic differentiation of human osteosarcoma  
5 MG63 cells. *J Biomed Mater Res B Appl Biomater* 2011,98B:300-7.

6  
7 32 Jayalakshmi KB, Agarwal S, Singh MP, *et al.* Platelet-Rich Fibrin with  $\beta$   
8 -Tricalcium Phosphate-A Noval Approach for Bone Augmentation in Chronic  
9 Periapical Lesion: A Case Report. *Case Rep Dent* 2012,2012:902858.

10  
11 33 Cortellini S, Castro AB, Temmerman A, *et al.* Leucocyte- and platelet-rich fibrin  
12 block for bone augmentation procedure: A proof-of-concept study. *J Clin Periodontol*  
13 2018,45:624-34.

14  
15 34 Lei L, Yu Y, Ke T, *et al.* The Application of Three-Dimensional Printing Model  
16 and Platelet-Rich Fibrin Technology in Guided Tissue Regeneration Surgery for  
17 Severe Bone Defects. *J Oral Implantol* 2019,45:35-43.

18  
19 35 Sezgin Y, Uraz A, Taner IL, *et al.* Effects of platelet-rich fibrin on healing of  
20 intra-bony defects treated with anorganic bovine bone mineral. *Braz Oral Res*  
21 2017,31:e15.

22  
23 36 Fickl S, Kerschull M, Schupbach P, *et al.* Bone loss after full-thickness and  
24 partial-thickness flap elevation. *J Clin Periodontol* 2011,38:157-62.

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 **Figure Legend:**

51  
52 **Figure 1** The flow chart of this clinical research  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 The flow chart of this clinical research  
189x175mm (600 x 600 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	11
Funding	4	Sources and types of financial, material, and other Support	12
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 2, 11
	5b	Name and contact information for the trial sponsor	12
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for Undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5, 6
	6b	Explanation for choice of comparators	6
Objectives	7	Specific objectives or hypotheses	6

1				
2	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
3				
4				
5				
6				
7				
8	<b>Methods: Participants, interventions, and outcomes</b>			
9				
10	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6, 7
11				
12				
13				
14	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
15				
16				
17				
18				
19	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8
20				
21				
22		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
23				
24				
25				
26				
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	N/A
29				
30				
31				
32		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
33				
34				
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8, 9
36				
37				
38				
39				
40				
41				
42				
43				
44				
45	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7, 8, 9
46				
47				
48				
49	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	9, 10
50				
51				
52				
53				
54	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7
55				
56				

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

1				
2	Sequence	16a	Method of generating the allocation sequence	7, 8
3	generation		(eg, computer-generated random numbers), and list of	
4			any factors for stratification. To reduce predictability of a	
5			random sequence, details of any planned restriction (eg, blocking)	
6			should be provided in a separate document that is unavailable to	
7			those who enrol participants or assign interventions	
8				
9				
10	Allocation	16b	Mechanism of implementing the allocation sequence	7, 8
11	concealment		(eg, central telephone; sequentially numbered, opaque, sealed	
12	mechanism		envelopes), describing any steps to conceal the sequence until	
13			interventions are assigned	
14				
15	Implementation	16c	Who will generate the allocation sequence,	7, 8
16			who will enrol participants, and who will assign participants to	
17			interventions	
18				
19				
20	Blinding	17a	Who will be blinded after assignment to interventions	8, 9
21	(masking)		(eg, trial participants, care providers, outcome assessors,	
22			data analysts), and how	
23				
24				
25		17b	If blinded, circumstances under which unblinding	N/A
26			is permissible, and procedure for revealing a participant's	
27			allocated intervention during the trial	
28				
29	<b>Methods: Data collection, management, and analysis</b>			
30				
31	Data collection	18a	Plans for assessment and collection of outcome, baseline	8, 9
32	methods		and other trial data, including any related processes to	
33			promote data quality (eg, duplicate measurements, training of	
34			assessors) and a description of study instruments	
35			(eg, questionnaires, laboratory tests) along with their	
36			reliability and validity, if known. Reference to where data	
37			collection forms can be found, if not in the protocol	
38				
39				
40				
41		18b	Plans to promote participant retention and complete	9, 10
42			follow-up, including list of any outcome data to be collected	
43			for participants who discontinue or deviate from intervention protocols	
44				
45	Data	19	Plans for data entry, coding, security, and storage,	9
46	management		including any related processes to promote data quality	
47			(eg, double data entry; range checks for data values). Reference to	
48			where details of data management procedures can be found, if not in	
49			the protocol	
50				
51				
52	Statistical	20a	Statistical methods for analysing primary and secondary	10
53	methods		outcomes. Reference to where other details of the statistical	
54			analysis plan can be found, if not in the protocol	
55				
56		20b	Methods for any additional analyses (eg, subgroup and	N/A
57			adjusted analyses)	
58				
59				
60				

1				
2		20c	Definition of analysis population relating to protocol	N/A
3			non-adherence (eg, as randomised analysis), and any	
4			statistical methods to handle missing data (eg, multiple imputation)	
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

### Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	9
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	9
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	9

### Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	11
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	N/A
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	11
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	12
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	11

1				
2	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for	N/A
3	post-trial care		compensation to those who suffer harm from trial participation	
4				
5	Dissemination	31a	Plans for investigators and sponsor to communicate trial	11
6	policy		results to participants, healthcare professionals, the public,	
7			and other relevant groups (eg, via publication, reporting in	
8			results databases, or other data sharing arrangements),	
9			including any publication restrictions	
10				
11		31b	Authorship eligibility guidelines and any intended use of	N/A
12			professional writers	
13				
14		31c	Plans, if any, for granting public access to the full protocol,	N/A
15			participant-level dataset, and statistical code	
16				
17				
18				
19	<b>Appendices</b>			
20				
21	Informed consent	32	Model consent form and other related documentation	Additional file
22	materials		given to participants and authorised surrogates	
23				
24	Biological	33	Plans for collection, laboratory evaluation, and storage	N/A
25	specimens		Of biological specimens for genetic or molecular analysis in the	
26			current trial and for future use in ancillary studies, if applicable	
27				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.